Methods for stabilizing proteins
By controlling redox potential and oxygen tension during protein expression in mammalian cells, the method stabilizes recombinant proteins, addressing cost and quality issues in protein production.
Patent Information
- Application Number
- JP2022149473
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-06-10
- Filing Date
- 2022-09-20
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2037-06-12
AI Technical Summary
The high costs associated with producing recombinant therapeutic proteins in mammalian cell lines are exacerbated by product dissociation events that compromise protein stability and activity, which are not effectively detected by current quality control methods.
Maintaining a specific redox potential difference during cell separation and supernatant collection, along with controlled oxygen tension and temperature adjustments, to inhibit polypeptide dissociation in recombinant host cells.
This approach stabilizes expressed proteins by reducing dissociation events, enhancing production yields and quality, making them suitable for therapeutic use.
Smart Images

Figure 0007584206000020 
Figure 0007584206000021 
Figure 0007584206000022
Abstract
Description
[Technical field]
[0001] This application claims priority to U.S. Patent Application No. 62 / 348,595, filed June 10, 2016, the entire contents of which are incorporated herein by reference.
[0002] The present disclosure relates to methods and compositions for inhibiting the dissociation of cell products, such as polypeptides, expressed in cultured cells. [Background technology]
[0003] Cellular products, such as recombinant therapeutic proteins, are generally expressed in cellular expression systems, e.g., mammalian cell expression systems. Hundreds of biopharmaceuticals approved for marketing are expressed in mammalian cell systems. However, the high costs associated with their production contribute to the increase in global healthcare costs. Product dissociation events can result in lower than expected stability or activity of proteins or polypeptides expressed from cells grown in cell culture. These events are detected by non-reducing SDS electrophoresis assays, which reveal the presence of polypeptide product dissociation, along with trace amounts of normal product. Other quality control tests do not reveal polypeptide dissociation events. Summary of the Invention [Problem to be solved by the invention]
[0004] Furthermore, product dissociation events can impair the function and stability of the expressed protein. Thus, there is a need to develop and create methods to suppress dissociation of expressed polypeptides in cultured cells. [Means for solving the problem]
[0005] The present disclosure is based, in part, on the discovery that a number of measures, identified below, can inhibit dissociation of an expressed product, eg, a polypeptide.
[0006] In one aspect, the invention provides a method for producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: maintaining a redox potential difference from unstabilized product to stabilized product in the range of -50 mV to -300 mV during separation of cells from the production culture and harvest of supernatant, wherein separation of cells from the production culture and harvest of supernatant is performed without sparging or with sufficiently little sparging such that sparging does not substantially change the redox potential in the production culture and supernatant. Including, Thereby producing a stabilized product, e.g., an isolated stabilized protein. The present invention is characterized by a method.
[0007] In another aspect, the invention provides a method for producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: providing, e.g., establishing, in a production culture in a post-exponential growth culture phase, a redox potential difference from non-stabilized product to stabilized product in the range of -50 mV to -300 mV; maintaining a redox potential difference from the unstabilized product to the stabilized product in the range of -50 mV to -300 mV during separation of the cells from the production culture and the harvest of the supernatant, the separation of the cells from the production culture and the harvest of the supernatant being performed without sparging or with sparging sufficiently light that the sparging does not substantially change the redox potential in the production culture and the supernatant; Including, Thereby producing a stabilized product, e.g., an isolated stabilized protein. The present invention is characterized by a method.
[0008] In another aspect, the invention provides a method for producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: Providing, e.g., establishing, in a late logarithmic growth production culture, an oxidation-reduction potential difference from unstabilized product to stabilized product in the range of -50 mV to -300 mV, and a dissolved oxygen tension (DOT) from the beginning of the production phase to the end of the production phase in the range of greater than 40% to 70% air saturation; The production culture is cultured at the end of the production phase at a temperature at or below which the cell line is normally cultured, T 回収 and cooling to a temperature of increasing the DOT to a range of greater than 40% to less than 500% air saturation by sparging air or O2 gas into the production culture until separation of the cells from the production culture and harvesting of the supernatant; maintaining a redox potential difference from the unstabilized product to the stabilized product in the range of -50 mV to -300 mV during separation of the cells from the production culture and the harvest of the supernatant, the separation of the cells from the production culture and the harvest of the supernatant being performed without sparging or with sparging sufficiently light that the sparging does not substantially change the redox potential in the production culture and the supernatant; Including, Thereby producing a stabilized product, e.g., an isolated stabilized protein. The present invention is characterized by a method.
[0009] In another aspect, the invention provides a method for producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: (i) providing, e.g., establishing, a production culture, e.g., a post-logarithmic culture, with a redox potential difference from unstabilized to stabilized product in the range of -50 mV to -300 mV; (ii) maintaining the redox potential difference between the non-stabilized product and the stabilized product in the range of −50 mV to −300 mV during the late logarithmic growth culture; (iii) maintaining a redox potential difference from the unstabilized product to the stabilized product in the range of -50 mV to -300 mV during separation of the cells from the production culture and the harvest of the supernatant, wherein the separation of the cells from the production culture and the harvest of the supernatant is performed without sparging or with sufficiently little sparging such that the sparging does not substantially change the redox potential in the production culture and the supernatant; Including, The method is a. cooling the production culture to a temperature of 30° C. to 33° C., which is below the temperature at which the cell line is normally cultured or will normally be cultured after exponential growth phase has occurred; b. oxygenating the production culture from greater than 40% air saturation to less than or equal to 70% dissolved oxygen tension (DOT) from the beginning of the production phase to the end of the production phase; c. Providing, e.g., adding, a transition metal to or in the production culture, the transition metal ion being Zn 2+ , Mn 4+ , Cu 2+ , Fe 3+ , Co 2+ , Cr 3+ and / or Ni 2+ A step selected from the group consisting of: d. providing, e.g., adding, dehydroascorbic acid or ascorbic acid, or a dehydroascorbic acid or ascorbic acid modifying component to the production culture; e. providing, e.g., adding, glutathione, e.g., oxidized and / or reduced glutathione, or a glutathione modifying component, to the production culture; or f. The production culture is subjected to T for separation of cells from the production culture and harvest of the supernatant. 産生 Temperatures below 12°C to 18°C (T 回収 Cooling to temperature Including, thereby producing a stabilized product, e.g., an isolated stabilized protein, or a preparation of a stabilized product, e.g., a stabilized protein; The present invention is characterized by a method.
[0010] In another aspect, the invention features a stabilized protein, or a stable protein preparation, produced by the methods described herein.
[0011] In another aspect, the invention features a pharmaceutical composition comprising a stabilized protein, or a preparation of a stabilized protein, produced by the methods described herein.
[0012] In another aspect, the invention features a bioreactor capable of producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, wherein the bioreactor is capable of maintaining a redox potential difference from non-stabilized product to stabilized product in a range of -50 mV to -300 mV during separation of cells from the production culture and harvest of supernatant, and wherein separation of cells from the production culture and harvest of supernatant is performed without sparging or with sparging sufficiently low that the sparging does not substantially change the redox potential in the production culture and supernatant.
[0013] In another aspect, the invention provides a bioreactor capable of producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, the bioreactor comprising: In a post-logarithmic growth phase production culture, a redox potential difference from non-stabilized product to stabilized product can be provided, e.g., established, in the range of -50 mV to -300 mV; and During the separation of cells from the production culture and the harvest of the supernatant, the redox potential difference from the unstabilized product to the stabilized product can be maintained in the range of -50 mV to -300 mV, and the separation of cells from the production culture and the harvest of the supernatant is performed without sparging or with sufficiently little sparging that the sparging does not substantially change the redox potential in the production culture and the supernatant. The present invention features a bioreactor.
[0014] In another aspect, the invention provides a bioreactor capable of producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, the bioreactor comprising: providing, e.g., capable of establishing, in a post-logarithmic growth phase production culture, a redox potential difference from unstabilized product to stabilized product in the range of -50 mV to -300 mV, and a dissolved oxygen tension (DOT) from the beginning of the production phase to the end of the production phase in the range of greater than 40% air saturation to 70% air saturation; The production culture is cultured at the end of the production phase at a temperature at or below which the cell line is normally cultured, T 回収 It is possible to cool to a temperature; By sparging air or O2 gas into the production culture prior to removal of the production culture from the bioreactor, the DOT can be increased to a range of greater than 40% air saturation to less than 500% air saturation; and During the separation of cells from the production culture and the harvest of the supernatant, the redox potential difference from the unstabilized product to the stabilized product can be maintained in the range of -50 mV to -300 mV, and the separation of cells from the production culture and the harvest of the supernatant is performed without sparging or with sufficiently little sparging that the sparging does not substantially change the redox potential in the production culture and the supernatant. The present invention features a bioreactor.
[0015] In another aspect, the invention provides a bioreactor capable of producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, the bioreactor comprising: (i) providing, e.g., being capable of establishing, a production culture, e.g., a post-logarithmic culture, comprising recombinant host cells expressing a product, e.g., a protein, with a redox potential difference from unstabilized to stabilized product in the range of −50 mV to −300 mV; (ii) the redox potential difference between the non-stabilized product and the stabilized product after the logarithmic growth phase can be maintained in the range of -50 mV to -300 mV; and (iii) during separation of the cells from the production culture and the harvest of the supernatant, the redox potential difference from the unstabilized product to the stabilized product can be maintained in the range of -50 mV to -300 mV, and the separation of the cells from the production culture and the harvest of the supernatant is performed without sparging or with sufficiently little sparging that the sparging does not substantially change the redox potential in the production culture and the supernatant; The bioreactor further comprises: a. The production culture can be cooled to a temperature of 30° C. to 33° C. after logarithmic growth phase has occurred, which is a temperature below the temperature at which the cell line is normally cultured or will normally be cultured; b. The production culture is capable of being oxygenated to a dissolved oxygen tension (DOT) of greater than 40% up to and including 70% of air saturation from the beginning of the production phase to the end of the production phase; c. Ions of a transition metal can be provided, e.g., added, in or to the production culture, the transition metal ion being Zn 2+ , Mn 4+ , Cu 2+ , Fe 3+ , Co 2+ , Cr 3+ and / or Ni 2+ Selected from; d. dehydroascorbic acid or ascorbic acid, or a dehydroascorbic acid or ascorbic acid modifying component, can be provided, e.g., added, to the production culture; e. glutathione, e.g., oxidized and / or reduced glutathione, or a glutathione modifying component, can be provided, e.g., added, to the production culture; or f. The production culture is subjected to T for separation of cells from the production culture and harvest of the supernatant. 産生 Temperatures below 12°C to 18°C (T 回収 It is possible to cool to a temperature The present invention features a bioreactor.
[0016] In one embodiment, the method disclosed herein includes a step of maintaining a number of conditions, e.g., the presence of feedstocks / supplements or any of the physicochemical conditions, to promote a more favorable redox potential in the production culture, e.g., during the growth phase, e.g., during the logarithmic growth phase, and the bioreactor disclosed herein is capable of maintaining a number of conditions, e.g., the presence of feedstocks / supplements or any of the physicochemical conditions, to promote a more favorable redox potential in the production culture, e.g., during the growth phase, e.g., during the logarithmic growth phase. Typically, the conditions are maintained, e.g., at least partially, at a later stage, e.g., during the harvesting stage or post-harvesting stage. By way of example, the conditions are maintained at a level that optimizes the production of a stabilized product, e.g., a stabilized protein, as the cells enter the harvesting and post-harvesting stages, and optionally until the product is isolated from background processes and cellular impurities.
[0017] In one embodiment, the feed material or supplement may, for example, be in the range of 200 to 400 μM Zn in the production culture, respectively. 2+ Residual concentrations of ions, as well as Mn in the range of 10 to 100 μM 2+ and Cu 2+ At levels that provide residual concentrations of the ion, Zn 2+ , Mn 2+ and Cu 2+ Contains salts of.
[0018] In one embodiment, the dissolved oxygen tension (DOT) of the production culture is maintained between at least 40% and 70% air saturation.
[0019] In one embodiment, the production culture is initially maintained at a first temperature, e.g., 36° C. to 37° C., and is changed to a second, typically lower temperature, e.g., 30° C. to 33° C., at a predetermined time point, e.g., when production has completed its growth phase. In one embodiment, the temperature of the production culture is initially controlled at 36° C. to 37° C., but then the temperature is controlled to 30° C. to 33° C. when the production culture begins to complete its growth phase, typically on days 5 to 7 of a 15 day production period.
[0020] In one embodiment, the method includes maintaining the redox potential of the production culture toward a relatively more oxidative potential, e.g., an oxidative potential that increases production of the stabilized product by, e.g., at least, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100%, by using one or more of the conditions described above, or the bioreactor is capable of maintaining the redox potential of the production culture toward a relatively more oxidative potential, e.g., an oxidative potential that increases production of the stabilized product by, e.g., at least, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100%, by using one or more of the conditions described above. Alternative means can also be used to shift the redox potential towards a more oxidative potential, these include other redox potential affecting components of the medium or changes in cellular metabolism to increase pro-oxidant metabolites such as dehydroascorbic acid / ascorbic acid, glutathione / glutathione-SH, and cysteine / cystine in combination with temperature and DOT.
[0021] In one embodiment, the method includes, or the bioreactor can use a marker, e.g., a dye or molecular probe, indicative of redox potential to sense changes in the redox potential of cells in the production culture that affect the appropriate process change, to prevent subsequent products expressed by the cells from dissociating. In one embodiment, the method includes, or the bioreactor can use an in-line monitoring probe for redox potential, e.g., a Mettler Toledo probe as described herein, to sense changes in the redox potential of cells in the production culture that affect the appropriate process change, to prevent subsequent products expressed by the cells from dissociating.
[0022] In one embodiment, the method includes using analytical methods to examine enzyme activity (e.g., glutathione reductase, thioredoxin, thioredoxin reductase) and / or a number of cofactors and associated metabolites (e.g., cofactors and associated metabolites associated with the pentose phosphate pathway, e.g., glucose-6-phosphate, NADPH, NADP+, 6-phosphonoglucolactone, 6-phosphogluconic acid, or ribulose-5-phosphate) involved in the product dissociation reaction and expressed by the cell line. In one embodiment, examining the enzyme activity and a number of cofactors and associated metabolites is used to select cell lines and clones with reduced or desired levels of cellular factors that do not promote product dissociation during further processing.
[0023] In one embodiment, the method includes, or the bioreactor is capable of cooling the cultured cells to 15±3° C. prior to separating the cultured cells from the product-containing supernatant using depth filtration or centrifugation and depth filtration steps.
[0024] In one embodiment, once the production culture has reached the target temperature at which the harvesting step begins, the method includes, or the bioreactor is capable of, ensuring that all factors that may compete with the oxygen load of the production culture are minimized, e.g., by process control. In an embodiment, the method includes, or the bioreactor is capable of, inhibiting sparge nitrogen gas flow, if effective, inhibiting on-demand alkali control, if effective, inhibiting on-demand CO2 gas flow control, if effective, or inhibiting feed application, if effective.
[0025] In one embodiment, once the production culture has reached the target temperature at which to begin the harvesting step, the method includes the step of ensuring that all factors that may promote oxygenation of the production culture are maximized and / or enabled, e.g., by controlling the process, or the bioreactor is capable of ensuring that all factors that may promote oxygenation of the production culture are maximized and / or enabled, e.g., by controlling the process.In an embodiment, the method includes one or more of the following steps: enabling sparge air gas flow if not effective; enabling sparge oxygen gas flow if not effective; enabling headspace pressure if not effective; enabling headspace air and / or oxygen flow if not effective; ensuring that the cell culture remains well mixed and aerated while draining during the harvest operation; ensuring that the bioreactor harvest line is designed with respect to internal pore size and wall strength to withstand collapse and interruption of the desired flow rate during the harvest operation; optimizing the area of the depth filter to avoid filter plugging and fouling during the filter clarification step, thereby increasing the residence time of the cell culture within the filter housing; and ensuring that the cell-free supernatant is collected in a well aerated and mixed collection vessel (steel or single use). or the bioreactor can include one or more of: enabling sparge air gas flow, if not effective; enabling sparge oxygen gas flow, if not effective; enabling headspace pressure, if not effective; enabling headspace air and / or oxygen flow, if not effective; ensuring that the cell culture remains well mixed and aerated while draining during the harvest operation; ensuring that the bioreactor harvest line is designed with internal pore size and wall strength to withstand collapse and obstruction of the desired flow rate during the harvest operation; optimizing the depth filter area to avoid filter plugging and fouling during the filter clarification step, thereby increasing the residence time of the cell culture within the filter housing; and ensuring that the cell-free supernatant is collected in a well aerated and mixed collection vessel (steel or single use).In embodiments, a collection vessel for use in a method is designed to ensure good surface oxygen loading by one or both of impinging the collected filtrate on the vessel wall by designing an internal nozzle towards the vessel wall that forces the filtrate to cascade down the vessel wall, and the ability to fill the collection vessel with a gaseous environment comprised of air or any given combination of air and oxygen prior to collection of the filtrate to promote oxygen loading of the collected filtrate to greater than >40% air saturation and ≦500% air saturation.
[0026] In an embodiment, it is proposed to monitor the flow paths between the bioreactor and the cell clarification step, and between the cell centrifugation step and the supernatant collection vessel, e.g., the harvest vessel, with redox, DOT and pH sensors. In addition, parameters in the bioreactor may be adjusted by varying redox, DOT and pH in the two flow paths or in the supernatant collection vessel, e.g., the harvest vessel.
[0027] In one aspect, the disclosure features a method for producing a product, e.g., a polypeptide, e.g., a recombinant polypeptide, by a cell, the method including providing a cell line that includes the cells and that includes a polynucleotide sequence that encodes the polypeptide. The production culture is cultured under conditions that allow for expression of the product, e.g., the polypeptide, and the production culture is cooled to a temperature of 30° C. to 33° C., which is below the temperature at which the cell line is or would normally be cultured, thereby making the product, e.g., the polypeptide. 回収 Further cooling of the production culture to a temperature, for example, 15° C., occurs at the end of the production phase.
[0028] In an embodiment, the product is a polypeptide that includes two or more cysteine residues, e.g., the first, second, third and fourth or more cysteine residues. In an embodiment, the polypeptide in its native form includes a sulfhydryl bond between the first and second cysteine residues. In an embodiment, the polypeptide includes a sulfhydryl bond between the third and fourth cysteine residues. In an embodiment, the T 回収 is sufficiently low to reduce the consumption of dissolved oxygen during the culture so that sufficient dissolved oxygen is available in the supernatant to prevent activation of cellular factors (both enzymatic and metabolic) and inhibit dissociation of disulfide bonds. 回収 For example, see T 回収 The cooling was not performed at a temperature sufficiently low to prevent dissociation of disulfide bonds by at least 10, 20, 30, 40, 50, 60, 70, 80, or 90%, as compared to the level of dissociation obtained from an otherwise similar process.
[0029] In an embodiment, the method comprises: 回収 and isolating the expressed polypeptide from the cultured cells.
[0030] In an embodiment, the method further comprises the step of: 回収 and purifying the expressed polypeptide when the culture is cooled to rt.
[0031] In an embodiment, the cell line is cultured at a first temperature, T 培養 After the logarithmic growth phase, 産生 At the end of the production phase, the extract is cooled to a temperature (e.g., 30° C. to 33° C.) and then cooled to a harvest temperature, T 回収 (e.g., to 12° C. to 18° C.). 培養 is T 産生 In an embodiment, T 産生 is T 回収 Higher.
[0032] In an embodiment, the T培養 Cells typically cultured at a T of 35°C, 34°C, 33°C, 32°C, 31°C, or less than 30°C. 産生 In embodiments, the culture is placed at a temperature of 29° C., 28° C., 27° C., 26° C., 25° C., 24° C., 23° C., 22° C., 21° C., 20° C., 19° C., 18° C., 17° C., 16° C., 15° C., 14° C., 13° C., 12° C., 11° C., 10° C., 9° C., 8° C., 7° C., 5° C., or 4° C., or at a T of less than 15° C., less than ambient temperature, and / or less than room temperature. 回収 In an embodiment, the temperature is further cooled to T 回収 In one embodiment, T 回収 is 15±3°C.
[0033] For example, in an embodiment, T 産生 is T 培養 At least 1°C, 3°C or 6°C lower than the above.
[0034] For example, in an embodiment, T 回収 is T 産生 At least 2°C, 5°C or 8°C lower than the above.
[0035] In an embodiment, the cultured cells are 回収 and separated from the supernatant.
[0036] In an embodiment, the separation step for separating the polypeptide from other components of the supernatant comprises 回収 It is held.
[0037] In an embodiment, for example, the polypeptide as a component of the supernatant is T 回収 is applied to the filter.
[0038] In an embodiment, the contents of the bioreactor are 回収 The mixture is cooled to .
[0039] In an embodiment, the cell culture is 回収 The material is cooled by contact with a member, such as a cooling jacket, that contains a fluid, such as water, at a temperature appropriate to effect the desired reaction.
[0040] In an embodiment, the method comprises: 培養 , T 産生 and / or T 回収 The method further comprises providing nutrients or oxygen during the step.
[0041] In an embodiment, the cell culture is 培養 , T 産生 and / or T 回収 In between, it is stirred.
[0042] In an embodiment, the method includes the step of recovering the expressed polypeptide.
[0043] In an embodiment, the cells or products thereof are 回収 And it's in the collection container.
[0044] In embodiments, the polypeptide is one of the polypeptides provided in Tables 1 and 2, or a variant thereof.
[0045] In an embodiment, the polypeptide is an antibody, for example, a monoclonal antibody, for example, an IgG1 antibody, or a polynucleotide encoding the antibody. In an embodiment, one or more cysteines in the polynucleotide encoding the antibody are replaced with another amino acid. In some embodiments, one or more cysteines are replaced with one or more serine residues.
[0046] In an embodiment, the cell line is derived from a mammalian cell.
[0047] In one aspect, the disclosure features a method for producing in a cell a product described herein. In one embodiment, the product is a polypeptide, e.g., a recombinant polypeptide.
[0048] Examples of products that may be produced using any of the methods or compositions described herein include recombinant products, or products where at least one portion or component is the result of genetic engineering. The recombinant products described herein are useful for diagnostic or therapeutic purposes. In one embodiment, the product comprises a polypeptide, such as an antibody molecule (e.g., a bispecific or multiformat antibody molecule), a fusion protein, or a protein complex. The methods and compositions described herein may be particularly useful for products that are difficult to produce in large quantities or in sufficient quality for commercial or therapeutic use, such as, for example, next generation biologics (e.g., fusion proteins, bispecific or multiformat antibody molecules, multimeric proteins, and glycosylated proteins). In one embodiment, the cells described herein, for example, for producing a product, express the product. In one embodiment, the cells comprise an exogenous nucleic acid encoding a product described herein, e.g., a polypeptide selected from Table 1, Table 2, Table 3, or Table 4. Additional examples of products are described in the section entitled "Products."
[0049] In such embodiments, an increase or decrease in any of the aforementioned cellular properties can be determined by comparison to cells that do not have the alteration.
[0050] The methods and bioreactors described herein result in increased production of a product compared to cells not subjected to lower temperatures. Increased production can be characterized as an increase in the amount, yield, or number of product produced by the cells, and / or an increase in the rate of production, where the rate of production is equivalent to the amount of product over time. In one embodiment, production of a product, e.g., a recombinant polypeptide, is increased, e.g., 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, compared to production by cells not subjected to lower temperatures.
[0051] The methods and bioreactors described herein can also result in improved product quality compared to cells not subjected to lower temperatures. The improved product quality can have one or more properties of dissociation (e.g., reduced dissociation of polypeptides into less active forms); aggregation (e.g., reduced aggregates or aggregation); proper folding or assembly (e.g., reduced misfolded or unfolded products; or partially assembled or degraded products); post-translational modifications (e.g., increased or decreased glycosylation heterogeneity, higher percentage of desired or predetermined post-translational modifications); fragmentation (e.g., reduced fragmentation); disulfide bond scrambling (e.g., reduced undesired isoforms or structures due to disulfide bond scrambling). In one embodiment, the quality of the product, e.g., recombinant polypeptide, is improved, e.g., 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, compared to the quality of the product produced by cells not subjected to lower temperatures.
[0052] In an embodiment, the method for producing the product described herein can be performed with one or more additional steps to enhance the stability or activity of the polypeptide. Additional steps include, but are not limited to, introducing a modification into the cell that improves the processing capacity of the ER (ER expansion) or secretion; obtaining the product from the cell or from a progeny of the cell or from a medium conditioned by the cell or from a progeny of the cell; separating the product from at least one cellular or medium component; and / or analyzing the product, for example, for the activity or presence of a structural moiety. In one embodiment, the method further comprises a step to improve the processing capacity of the ER (or ER expansion) by introducing a nucleic acid encoding PD1, BiP, ERO, or XBP1. In one embodiment, the method further comprises a step to improve the secretion capacity or rate of secretion by modulating the SNARE machinery or other mechanisms involved in the secretory pathway, for example, by introducing a nucleic acid encoding a SNARE component.
[0053] product Suitable products for the methods described herein include polypeptides, e.g., recombinant proteins; nucleic acid molecules, e.g., DNA or RNA molecules; multimeric proteins or complexes; lipid encapsulated particles, e.g., virus-like particles, vesicles or exosomes; or other molecules. In one embodiment, the product is a polypeptide, e.g., a recombinant polypeptide. For example, recombinant polypeptides may be difficult to express proteins, such as next generation biologics, e.g., bispecific antibody molecules, fusion proteins, or glycosylated proteins, or complexes and / or proteins with non-native structures.
[0054] In any of the methods described herein, the method for producing a product further includes the step of introducing an exogenous nucleic acid into the cell, the exogenous nucleic acid encoding the product, e.g., a polypeptide, e.g., a recombinant polypeptide.
[0055] In any of the compositions, preparations, bioreactors or methods described herein, the product, e.g., recombinant polypeptide, is a therapeutic polypeptide or an antibody molecule, e.g., an antibody, or an antibody fragment thereof. In one embodiment, the antibody molecule is a monoclonal antibody. In one embodiment, the antibody molecule is a bispecific antibody molecule, e.g., BiTE (bispecific T cell targeting), DART (dual affinity retargeted or redirected T cells).
[0056] In one embodiment, the product, eg, a recombinant polypeptide, is selected from Table 1, Table 2, Table 3, or Table 4.
[0057] In an embodiment, the product is stably expressed by the cell. In one embodiment, the exogenous nucleic acid encoding the product, e.g., a recombinant polypeptide, is integrated into the chromosomal genome of the cell. Alternatively, the product is transiently expressed by the cell. In one embodiment, the exogenous nucleic acid encoding the product, e.g., a recombinant polypeptide, is not integrated into the chromosomal genome of the cell.
[0058] host cell Provided herein are cells and methods for genetically engineering such cells to produce the products described herein.
[0059] In any of the compositions, preparations, or methods described herein, the cell is a eukaryotic cell. In one embodiment, the cell is a mammalian cell, a yeast cell, an insect cell, an algae cell, or a plant cell. In one embodiment, the cell is a rodent cell. In one embodiment, the cell is a CHO cell. Examples of CHO cells include, but are not limited to, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, CHOZN, or CHO derived cells.
[0060] In any of the compositions, preparations, or methods described herein, the cells are selected from the group consisting of HeLa, HEK293, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK, VERO, SP2 / 0, NS0, YB2 / 0, EB66, C127, L cells, COS, e.g., COS1 and COS7, QC1-3, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, and CHOZN.
[0061] In one embodiment, the cell is a eukaryotic cell other than a mammalian cell, such as an insect cell, a plant cell, a yeast cell or an algae cell. In one embodiment, the cell is a prokaryotic cell.
[0062] In any of the methods or cells, e.g., genetically engineered cells, described herein, the cells express or contain a product, e.g., a recombinant product, e.g., a next generation biologic selected from the group consisting of a bispecific antibody, a fusion protein, or a glycosylated protein.
[0063] In any of the methods or cells, e.g., genetically engineered cells, described herein, the cell is a CHO cell selected from the group consisting of CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, CHOZN or a CHO derived cell.
[0064] Compositions and Preparations In one aspect, the disclosure also features a preparation of a product described herein made by a method described herein. In one embodiment, at least 70, 80, 90, 95, 98, or 99% of the products in the preparation, by weight or number, are properly folded or assembled. In one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5% of the products in the preparation, by weight or number, are aggregated. In one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5% of the products in the preparation, by weight or number, are product fragments.
[0065] In one aspect, the disclosure features a mixture comprising a cell, e.g., a cell, as described herein, and a product produced by the cell. In one embodiment, the mixture comprises a higher concentration of the product, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, or 30% higher by weight or number of products than would be found without the disclosed process parameters. In one embodiment, at least 70, 80, 90, 95, 98, or 99% of the products in the mixture, by weight or number, are properly folded or assembled. In one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5% of the products in the mixture, by weight or number, are aggregated. In one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5% of the products in the mixture, by weight or number, are product fragments.
[0066] In one aspect, the disclosure features a preparation of medium conditioned by culturing cells subjected to a temperature-reducing modification as described herein. In one embodiment, the product is present in the preparation at a higher concentration, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, or 30% 100% higher by weight or number than found without the modification. In one embodiment, at least 70, 80, 90, 95, 98, or 99% of the products in the preparation, by weight or number, are properly folded or assembled. In one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5% of the products in the preparation, by weight or number, are aggregated. In one embodiment, less than 50%, 40%, 30%, 25%, 20%, 15%, 10% or 5% by weight or number of the products in a preparation are fragments of the product.
[0067] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are for illustrative purposes only and are not intended to be limiting. Headings, subheadings, or numbered or lettered elements, such as (a), (b), (i), etc., are presented merely for ease of reading. The use of headings or numbered or lettered elements herein does not require that the steps or elements be performed in alphabetical order or that the steps or elements are necessarily separate from one another. Other features, objects, and advantages of the present invention will become apparent from the specification and drawings, and from the claims. [Brief description of the drawings]
[0068] [Figure 1] FIG. 1 shows the interrelationships of temperature, oxygen solubility and oxygen uptake rate (OUR). [Diagram 2] Schematic representation of a mitigation scheme for minimizing dissociation of polypeptides in the bioreactor, primary recovery enclosure, and storage device. [Diagram 3] FIG. 1 shows the harvest profiles of two bioreactors with and without harvest oxygen loading, without and with abatement including cell cooling. [Figure 4] FIG. 1 shows non-reducing SDS-polyacrylamide gel samples prepared without (left panel) and with (right panel) reduction for an IgG1 monoclonal antibody. [Diagram 5] 1 is a graph of the redox potential of the production culture over the culture period for a baseline upstream process and for an optimized upstream process using bolus addition of micronutrients or continuous addition of micronutrients. [Figure 6] 1 is a graph of air and oxygen sparge flow and production culture temperature versus intracellular oxygen demand (sLPM) over time, labeling steps and transition points. [Figure 7A] FIG. 1 shows an example of a control profile of a culture when sparged air and oxygen are fixed in the production culture during harvest. [Figure 7B] FIG. 1 shows an example of a control profile of a culture where sparged air and oxygen were fixed in a production culture during harvest to limit the culture's DOT to approximately 200% maximum air saturation. [Figure 8A] Schematic diagram of an example bioreactor and harvest vessel with the flows, parts and functions of the culture labeled. [Figure 8B] FIG. 8B is a labeled enlarged view of the encircled headspace area of the collection vessel of FIG. 8A. [Figure 9] FIG. 2 is a diagram of an example collection container. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0069] The present disclosure features methods and compositions for obtaining higher yields of products by cooling cell cultures. Thus, the cells exhibit improved quality compared to the yields and quality obtained from current production methods. The methods and compositions described herein are also useful for genetic engineering of cells or cell lines with improved productivity, product quality, robustness and / or culture viability compared to cell expression systems currently used to produce recombinant products.
[0070] The method is suitable for producing next-generation biologics. As these methods continue to increase therapeutic utility in patients, the demand for large quantities of next-generation biologics with high-grade quality for therapeutic use, as well as efficient means for production and efficient development of production cell lines, will increase. Furthermore, many next-generation biologics are difficult to express and produce in conventional cell systems using conventional expression techniques known in the art. Current methods are not sufficient to produce these products in the large quantities and high-grade quality required for clinical use. The cooling method described herein overcomes these obstacles.
[0071] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice and / or testing of the present invention, the preferred materials and methods are described herein. In the description and claims of the present invention, when a definition is provided, the following terminology will be used according to how it is defined.
[0072] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0073] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "a cell" can mean one cell or more than one cell.
[0074] As used herein, "dissociation" refers to the cleavage or dissociation of disulfide bonds via reduction between cysteine residues within and between polypeptides.
[0075] As used herein, "endogenous" refers to any substance that is naturally produced from or within an organ, cell, tissue or system.
[0076] As used herein, "exogenous" refers to any substance that is introduced into or produced outside of an organ, cell, tissue, or system. Thus, an "exogenous nucleic acid" refers to a nucleic acid that is introduced into or produced outside of an organ, cell, tissue, or system. In one embodiment, the sequence of the exogenous nucleic acid is not naturally produced or cannot be found naturally inside the organ, cell, tissue, or system into which the exogenous nucleic acid has been introduced. In an embodiment, a non-naturally occurring product, or a product that contains a non-naturally occurring protein, is an exogenous substance to the host cell described herein.
[0077] As used herein, "heterologous" refers to any material from one species when introduced into an organ, cell, tissue, or system from a different species. In embodiments, heterologous material also encompasses material that includes portions from one or more species, or portions that do not occur naturally. As an example, in one embodiment, a nucleic acid encoding a fusion protein, where one portion of the fusion protein is human, one portion of the fusion protein is bacterial, and one portion of the fusion protein is not naturally occurring, and the nucleic acid is introduced into a human cell, is a heterologous nucleic acid.
[0078] "Peptide", "polypeptide" and "protein" as used interchangeably herein refer to compounds that contain amino acid residues that are covalently linked by peptide bonds or by means other than peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that may comprise a protein or peptide sequence. In one embodiment, a protein may be composed of two or more polypeptides, e.g., two, three, four, five or more, each of which is associated with each other by either covalent or non-covalent bonds / interactions. A polypeptide includes any peptide or protein that contains two or more amino acids that are linked to each other by peptide bonds or by means other than peptide bonds. As used herein, the term refers to both short chains, also commonly referred to in the art as peptides, oligopeptides and oligomers, and longer chains, of which there are many varieties in the art, commonly referred to as proteins. "Polypeptides" include, for example, biologically active fragments, substantially homogeneous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins, among others.
[0079] "Recombinant product" refers to a product that can be produced by a cellular or cell-free system. The product can be a molecule, a nucleic acid, a polypeptide, or any hybrid thereof. A recombinant product is one in which at least one component of the product, or at least one nucleotide of a sequence that controls the production or expression of the product, has been formed by genetic engineering. Genetic engineering used herein to generate recombinant products or constructs that encode recombinant products includes recombinant DNA expression techniques known in the art (e.g., those described in Current Protocols in Molecular Biology); site-directed scanning or random mutagenesis; CRISPR strategies; and zinc finger nuclease (ZFN) strategies. In one embodiment, the recombinant product is a recombinant polypeptide. In one embodiment, the recombinant product is a naturally occurring product. In one embodiment, the recombinant product is a non-naturally occurring product, e.g., a synthetic product. In one embodiment, a portion of the recombinant product is naturally occurring, while another portion of the recombinant product is not naturally occurring. In another embodiment, a first portion of the recombinant product is one naturally occurring molecule, while another portion of the recombinant product is another naturally occurring molecule that is different from the first portion. In some embodiments, a recombinant product (e.g., a recombinant polypeptide) is a stabilized product. A stabilized product is a product produced by a cell, e.g., a recombinant host cell, under conditions that increase the likelihood of proper folding and binding sequences, e.g., correct pairing of disulfide bonds, and decrease the likelihood of dissociation of the multi-subunit polypeptide. In some embodiments, a stabilized product is a stabilized protein. A stabilized protein is a protein produced by a cell under conditions that increase the likelihood of proper protein folding and binding sequences, e.g., proper disulfide bond binding, and decrease the likelihood of dissociation of the multi-subunit polypeptide.For example, a stabilized protein may be produced at a temperature and oxygenation level that creates an oxidative environment relative to the temperature and oxygenation level used to produce a non-stabilized protein, which increases the likelihood of maintaining the correct disulfide bonds and decreases the likelihood that the multi-subunit polypeptides may dissociate from one another. A stabilized product, e.g., a stabilized protein, may also be isolated, e.g., purified, from a cell or cell culture by a series of separation / chromatographic steps under conditions that promote proper folding and binding sequences. A preparation of a stabilized product, e.g., a stabilized protein, is a preparation that is prepared, e.g., from a cell, e.g., a recombinant host cell, under conditions that increase the likelihood of proper folding and binding sequences and decrease the likelihood of dissociation of the multi-subunit polypeptide. For example, a preparation of a stabilized product, e.g., a stabilized protein, is more likely to contain a product, e.g., a protein, with the correct disulfide bonds and less likely to contain a dissociated product, e.g., a protein, e.g., a dissociated subunit of a multi-subunit polypeptide. For more in-depth discussions on the topic of dissociation of products such as antibodies, see, for example, Wai Keen Chung et al., 2017, Michael W Handlogten et al., 2017, and Brian Mullan et al., 2011.
[0080] "Recombinant polypeptide" refers to a polypeptide that can be produced by a cell as described herein. A recombinant polypeptide is one in which at least one nucleotide sequence encoding the polypeptide or at least one nucleotide sequence controlling the expression of the polypeptide has been formed by genetic engineering or manipulation (of a cell or a precursor cell). For example, it is a product in which at least one nucleotide has been altered, e.g., introduced into a cell or rearranged genetically. In one embodiment, the sequence of the recombinant polypeptide does not differ from a naturally occurring or non-naturally occurring isoform of the polypeptide or protein. In one embodiment, the amino acid sequence of the recombinant polypeptide differs from the sequence of a naturally occurring or non-naturally occurring isoform of the polypeptide or protein. In one embodiment, the recombinant polypeptide and the cell are derived from the same species. In one embodiment, the amino acid sequence of the recombinant polypeptide is the same, or substantially the same, or is no more than 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% different from a polypeptide encoded by the endogenous genome of the cell. In one embodiment, the recombinant polypeptide and the cell are from the same species, e.g., the recombinant polypeptide is a human polypeptide and the cell is a human cell. In one embodiment, the recombinant polypeptide and the cell are from different species, e.g., the recombinant polypeptide is a human polypeptide and the cell is a non-human, e.g., rodent, e.g., CHO, other mammalian cell, insect cell, plant, fungal, or bacterial cell. In one embodiment, the recombinant polypeptide is exogenous to the cell, in other words, the cell is from a first species and the recombinant polypeptide is from a second species. In one embodiment, the polypeptide is a synthetic polypeptide. In one embodiment, the polypeptide is from a non-naturally occurring source.In one embodiment, the recombinant polypeptide is a human polypeptide or protein that does not differ in amino acid sequence from a naturally occurring or non-naturally occurring isoform of a human polypeptide or protein. In one embodiment, the recombinant polypeptide differs from a naturally occurring or non-naturally occurring isoform of a human polypeptide or protein by no more than 1, 2, 3, 4, 5, 10, 15, or 20 amino acid residues. In one embodiment, the recombinant polypeptide differs from a naturally occurring isoform of a human polypeptide by no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or 15% of its amino acid residues. In embodiments in which a portion of a recombinant polypeptide comprises a sequence derived from a portion of a naturally occurring or non-naturally occurring isoform of a human polypeptide, the portion of the recombinant polypeptide differs from the corresponding portion of the naturally occurring or non-naturally occurring isoform by no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues, or by no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or 15% of its amino acid residues.
[0081] Oxygenation level and level of oxygenation are used interchangeably and as used herein refer to the level of dissolved oxygen in a volume of liquid or gas, e.g., a medium. Oxygenation level can be described in units of dissolved oxygen tension (DOT), e.g., as a percentage of air saturation (e.g., the level of oxygen in air).
[0082] As used herein, a production culture refers to a mixture of a growth medium and a cell (e.g., at least one cell), e.g., a recombinant cell, e.g., a recombinant host cell expressing a product, e.g., a protein, a cellular factor, e.g., an enzyme, and a metabolite. In some embodiments, the production culture progresses through one or more culture phases (e.g., sequential and / or overlapping culture phases) that include characteristics of cell growth / division. In some embodiments, the treatment of the production culture varies as described herein as the production culture progresses through the different phases. As used herein, a production phase refers to a production culture phase that begins with seeding and ends when a particular criterion is reached (e.g., the end of a process or period, e.g., 10-30 days, e.g., 15-20 days) or when a particular cell viability criterion is reached (e.g., less than 90, 80, 70, 60, 50, 40, 30, 20, or 10% viability, e.g., less than 50% viability). The production phase may include a logarithmic growth phase, where cell growth and / or division is exponential. The production phase may include a post-logarithmic growth phase following the logarithmic growth phase, where cell growth and / or division is in the linear phase of the growth curve, e.g., the rate of cell growth and / or division is decreasing relative to the logarithmic growth phase. In some embodiments, separation of cells from the production supernatant, e.g., harvesting, and further separation or purification steps, e.g., post-harvesting, is the stage following the end of the production phase.
[0083] As used herein, redox potential difference refers to the comparison of redox potentials of two or more compounds, e.g., products, e.g., stabilized or non-stabilized products, e.g., stabilized or non-stabilized proteins. For example, a stabilized product may have redox potential A, while a non-stabilized product may have redox potential B; thus, the redox potential difference from stabilized product to non-stabilized product is AB (A minus B), or the redox potential difference from non-stabilized product to stabilized product is BA (B minus A). For example, the more negative the absolute redox potential, the more reducing the environment, and the goal of the present invention is to create a more oxidizing environment by the methods disclosed herein, thereby reducing the absolute negative redox potential toward a positive redox potential.
[0084] As used herein, operably linked refers to a relationship between vessels. In one embodiment, culture medium or production culture can be communicated between operably linked vessels. In one embodiment, the flow of culture between operably linked vessels occurs in a controlled manner, for example, using pumps, filters, sensors, means for maintaining or changing culture conditions, and / or means for monitoring fluid flow.
[0085] In some embodiments, the methods of the disclosure include maintaining the production culture, cells of the production culture, or supernatant from the production culture at different temperatures throughout different phases, or the bioreactors of the disclosure are capable of maintaining the production culture, cells of the production culture, or supernatant from the production culture at different temperatures throughout different phases. 培養 is the temperature at which the cells of the production culture grow, e.g., in the growth medium, from the beginning of inoculation to the end of the production phase to produce a production culture at which the protein is produced. In some embodiments, T 培養 As used herein, T 産生 is the first temperature to which the production culture is cooled after late logarithmic growth.産生 is 35°C, 34°C, 33°C, 32°C, 31°C or less than 30°C, for example, 30°C to 33°C. 回収 is the second temperature to which the production culture is cooled prior to harvesting (e.g., separation of the cells from the supernatant). In some embodiments, T 回収 is 29°C, 28°C, 27°C, 26°C, 25°C, 24°C, 23°C, 22°C, 21°C, 20°C, 19°C, 18°C, 17°C, 16°C, 15°C, 14°C, 13°C, 12°C, 11°C, 10°C, 9°C, 8°C, 7°C, 6°C, 5°C or 4°C. 回収 is 12°C to 18°C, for example, 15°C. 回収 is less than 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C or 24°C. 回収 is 15°C±3°C.
[0086] The disclosures of any and all patents, patent applications, and publications cited herein are hereby incorporated by reference in their entirety. Although the present invention has been disclosed with respect to certain embodiments, it is apparent that other embodiments and variations of the present invention may be devised by others skilled in the art without departing from the true spirit and scope of the present invention. It is intended that the appended claims be construed to include all such embodiments and equivalent variations.
[0087] product Provided herein are methods and compositions for engineering or creating cells or cell-free expression systems that can result in high product yields and / or improved product quality (e.g., stabilized products, e.g., stabilized proteins) by lowering the temperature at which the cells are expressed. The products described herein include polypeptides, e.g., recombinant proteins; multimeric proteins or complexes; lipid encapsulated particles, e.g., virus-like particles, vesicles, or exosomes; or other molecules. In one embodiment, the product is a polypeptide, e.g., a recombinant polypeptide. In one embodiment, the product is an exosome. For example, recombinant polypeptides can be difficult to express proteins, such as next generation biologics, e.g., bispecific antibody molecules, fusion proteins, or glycosylated proteins, or complexes and / or proteins with non-native structures.
[0088] In embodiments, the cells or cell lines generated by the methods or compositions described herein produce a product, e.g., a recombinant polypeptide, e.g., a stabilized protein, useful in the treatment of a medical condition, disorder, or disease, including, but not limited to, metabolic disease or disorders (e.g., metabolic enzyme deficiency), endocrine disorders (e.g., hormone deficiency), hemostatic dysregulation, thrombosis, hematopoietic disorders, pulmonary disorders, gastrointestinal disorders, autoimmune diseases, immune dysregulation (e.g., immunodeficiency), infertility, transplantation, cancer, and infectious diseases.
[0089] In an embodiment, the product is an exogenous protein, e.g., a protein that is not naturally expressed by the cell. In one embodiment, the protein is from one species, but the cell is from a different species. In another embodiment, the protein is a non-naturally occurring protein.
[0090] In other embodiments, the product is a protein endogenously expressed by the cell. In one embodiment, the product is a protein endogenously expressed by the cell at endogenous or natural levels. The methods and compositions described herein are used to increase the production and quality of an endogenous product, e.g., a naturally occurring product that is naturally produced by the cell. In another embodiment, an exogenous nucleic acid encoding a product, e.g., a protein, is introduced into the cell and expressed by the cell. In another embodiment, an exogenous nucleic acid is introduced into the cell that increases expression of a product exogenously expressed by the cell. By way of example, the exogenous nucleic acid includes a sequence that activates a promoter that controls expression of the endogenous product of the cell.
[0091] The recombinant product can be a therapeutic or diagnostic agent, useful, for example, for drug screening. Therapeutic or diagnostic agents can include, but are not limited to, antibody molecules, e.g., antibodies or antibody fragments, fusion proteins, hormones, cytokines, growth factors, enzymes, glycoproteins, lipoproteins, reporter proteins, therapeutic peptides, or structural and / or functional fragments or hybrids of any of these. In other embodiments, the therapeutic or diagnostic agent is a synthetic peptide, e.g., the entire polypeptide or a portion thereof is not derived from or has any sequence or structure similar to any naturally occurring polypeptide, e.g., the naturally occurring polypeptides listed above.
[0092] In one embodiment, the recombinant product is an antibody molecule. In one embodiment, the recombinant product is a therapeutic antibody molecule. In another embodiment, the recombinant product is a diagnostic antibody molecule, e.g., a monoclonal antibody useful in imaging techniques or diagnostic tests.
[0093] As used herein, an antibody molecule is a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. In one embodiment, the antibody molecule is a full-length antibody or an antibody fragment. Antibodies and multiformat proteins may be polyclonal or monoclonal, multi-chain or single-chain, or intact immunoglobulins and may be derived from natural or recombinant sources. The antibody may be a tetramer of immunoglobulin molecules. In one embodiment, the antibody is a monoclonal antibody. The antibody may be a human antibody or a humanized antibody. In one embodiment, the antibody is an IgA, IgG, IgD, or IgE antibody. In one embodiment, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.
[0094] "Antibody fragment" refers to at least a portion of an intact antibody, or a recombinant variant thereof, and refers to an antigen-binding domain, e.g., an antigen-determining variable region of an intact antibody sufficient to confer recognition and specific binding of the antibody fragment to a target, such as an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments, scFv antibody fragments, linear antibodies, single domain antibodies such as sdAbs (either VL or VH), camelid VHH domains, and multispecific antibodies formed from antibody fragments such as bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region, and isolated CDRs, or epitope-binding fragments of other antibodies. Antigen-binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen-binding fragments can also be grafted onto polypeptide-based scaffolds such as fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, describing fibronectin polypeptide minibodies).
[0095] In embodiments, the polypeptide is, for example, BOTOX, Myoblock, Neuroblock, Dysport (or other serotypes of botulinum neurotoxin), alglucosidase alfa, daptomycin, YH-16, chorionic gonadotropin alfa, filgrastim, cetrorelix, interleukin-2, aldesleukin, teceleulin, denileukin diftitox, interferon alfa-n3 (injection), interferon alfa-nl, DL-8234, interferon, Suntory (gamma-1a) , interferon gamma, thymosin alpha 1, tasonermin, DigiFab, ViperaTAb, EchiTAb, CroFab, nesiritide, abatacept, alefacept, Rebif, eptotermin alfa, teriparatide, calcitonin, etanercept, hemoglobin glutamer 250 (bovine), drotrecogin alfa, collagenase, carperitide, recombinant human epidermal growth factor, DWP401, darbepoetin alfa, epoetin omega, epoetin beta, epoetin alfa, desirudin, lepirudin, bivalirudin, nonaco Guar alpha, Mononine, Eptacog alfa (activated), recombinant factor VIII + VWF, Recombinate, recombinant factor VIII, factor VIII (recombinant), Alphnmate, Octocog alfa, factor VIII, Palifermin, Indikinase, Tenecteplase, Alteplase, Pamiteplase, Reteplase, Nateplase, Monteplase, Follitropin alfa, rFSH, hpFSH, Micafungin, Pegfilgrastim, Lenograstim, Nartograstim, Sermorelli glucagon, exenatide, pramlintide, imiglucerase, galsulfase, leukotropin, molgramostim, triptorelin acetate, histrelin (Hydrone), deslorelin, histrelin, nafarelin, leuprolide (Atrigel), leuprolide (Duros), goserelin, utropin, somatropin, mecasermin, enlfavirtide, Org-33408, insulin glargine, insulin glulisine, insulin (inhaled),Insulin lispro, insulin detemir, insulin (rapidmist), mecasermin linfavert, anakinra, cermoleukin, 99mTc-apsitide, myelopid, betaseron, glatiramer acetate, gepon, sargramostim, oprelvekin, human leukocyte-derived alpha interferon, virivu, insulin (recombinant), recombinant human insulin, insulin aspart, mecasenin, roferon-A, interferon-alpha 2, alphaferon, interferon alfacon-1, interferon alfa Fa, Avonex recombinant human luteinizing hormone, dornase alfa, trafermin, ziconotide, taltirelin, divotermin alfa, atosiban, becaplermin, eptifibatide, Zemaila, CTC-111, Shambac-B, octreotide, lanreotide, ancestim, agalsidase beta, agalsidase alfa, laronidase, copper acetate presatide, rasburicase, ranibizumab, Actimmune, PEG-Intron, Tricomin, recombinant human parathyroid hormone (PTH) 1-8 4, epoetin delta, transgenic antithrombin III, grandiotropin, vitrase, recombinant insulin, interferon-alpha, GEM-21S, vapreotide, idursulfase, omnapatrilat, recombinant serum albumin, certolizumab pegol, glucarpidase, human recombinant C1 esterase inhibitor, lanoteplase, recombinant human growth hormone, enfuvirtide, VGV-1, interferon (alpha), lucinactant, aviptadil, icatibant, ecallantide , Omiganan, Aurograb, Pexiganan acetate, ADI-PEG-20, LDI-200, Degarelix, Cintredelinbesudotox, Favld, MDX-1379, ISAtx-247, Liraglutide, Teriparatide, Tifacogin, AA4500, T4N5 liposomal lotion, Catumaxomab, DWP413, ART-123, Chrysalin (desmoteplase, amediplase, corifollitropin alfa, TH-9507, Teduglutide, Diamide, DWP-412,Growth hormone, recombinant G-CSF, insulin, insulin (Technosphere), insulin (AERx), RGN-303, DiaPep277, interferon beta, interferon alpha-n3, belatacept, transdermal insulin patch, AMG-531, MBP-8298, xerecept, opevacan, AIDSVAX, GV-1001, lymphoscan, ranpirnase, lipoxisan, rusplutide, MP52, sipuleucel-T, CTP-37, insedia, vitespen, human thrombin, thrombin, TransMID, al Fimmeplase, Precase, Terlipressin, EUR-1008M, recombinant FGF-I, BDM-E, Rotigaptide, ETC-216, P-113, MBI-594AN, Duramycin, SCV-07, OPI-45, Endostatin, Angiostatin, ABT-510, Bowman-Birk Inhibitor, XMP-629, 99mTc-Hynic-Annexin V, Kahalalide F, CTCE-9908, Teverelix, Ozarelix, Romidepsin, BAY-504798, Interleukin 4, PRX-321, PepScan , iboctadecin, rh lactoferrin, TRU-015, IL-21, ATN-161, cilengitide, albuferon, bifasix, IRX-2, omega interferon, PCK-3145, CAP-232, pasireotide, huN901-DM1, SB-249553, Oncovax-CL, Oncovax-P, BLP-25, Selvax-16, MART-1, gp100, tyrosinase, nemifitide, rAAT, CGRP, pegsnercept, thymosin beta 4, plitidepsin, GTP-200, ramoplanin, GRAS PA, OBI-1, AC-100, salmon calcitonin (Eligen), Examorelin, Capromorelin, Caldeva, Verafermin, 131I-TM-601, KK-220, T-10, Uraritide, Deperestat, Hematide, Chrysalin, rNAPc2, recombinant factor VIII (PEGylated liposome), bFGF, PEGylated recombinant staphylokinase variant, V-10153, Sonolysis Prolease, Neurovax, CZEN-002, rGLP-1, BIM-51077, LY-548806, Exenatide (extended release, Medisorb),AVE-0010, GA-GCB, avorelin, ACM-9604, linaclotide acetate, CETi-1, Hemospan, VAL, fast acting insulin (injection, Viadel), insulin (Eligen), recombinant methionyl human leptin, pitrakinra, multikine, RG-1068, MM-093, NBI-6024, AT-001, PI-0824, Org-39141, Cpn10, talactoferrin, rEV-131, rEV-131, recombinant human insulin, RPI-78M, oprelvekin, CYT-99007 CTLA4-Ig, DTY-001, Balategrast, Interferon alfa-n3, IRX-3, RDP-58, Tauferon, Bile salt-stimulated lipase, Melispase, Alaline phosphatase, EP-2104R, Melanotan-II, Bremelanotide, ATL-104, Recombinant human microplasmin, AX-200, SEMAX, ACV-1, Xen-2174, CJC-1008, Dynorphin A, SI-6603, LAB GHRH, AER-002, BGC-728, ALTU-135, recombinant neuraminidase, Vacc-5q, Vacc-4x, Tat toxoid, YSPSL, CHS-13340, PTH(1-34)(Novasome), Ostabolin-C, PTH analogue, MBRI-93.02, MTB72F, MVA-Ag85A, FARA04, BA-210, recombinant plague F1V, AG-702, OxSODrol, rBetV1, Der-p1 / Der-p2 / Der-p7, PR1 peptide antigen, mutant ras vaccine, HPV-16 E7 lipopeptide vaccine, Labirinthin, WT1-peptide, IDD-5, CDX-110, Pentris, Norelin, CytoFab, P-9808, VT-111, Icrocaptide, Telbermin, Rupintrivir, Reticulose, rGRF, HA, alpha-galactosidase A, ACE-011, ALTU-140, CGX-1160, Angiotensin, D-4F, ETC-642, APP-018, rhMBL, SCV-07, DRF-7295, ABT-828, ErbB2-specific immunotoxin, DT3SSIL-3, TST-10088, PRO-1762, Combotox, Cholecystokinin-B / gastrin receptor binding peptide, 111In-hEGF, AE-37,Trastuzumab-DM1, Antagonist G, IL-12, PM-02734, IMP-321, rhIGF-BP3, BLX-883, CUV-1647, L-19-based ra, Re-188-P-2045, AMG-386, DC / I540 / KLH, VX-001, AVE-9633, AC-9301, NY-ESO- 1 (peptide), NA17.A2 peptide, CBP-501, recombinant human lactoferrin, FX-06, AP-214, WAP-8294A2, ACP-HIP, SUN-11031, peptide YY[3-36], FGLL, atacicept, BR3-Fc, BN-003, BA-058, human parathyroid hormone 1-34, F-18-CCR1, AT-11, 00, JPD-003, PTH(7-34)(Novasome), duramycin, CAB-2, CTCE-0214, glycopegylated erythropoietin, EPO-Fc, CNTO-528, AMG-114, JR-013, factor XIII, aminocandin, PN-951, 716155, SUN-E7001, TH-0318, BAY-73-7977, teverelix, EP-51216, hGH, OGP-I, sifvirtide, TV4710, ALG-889, Org-41259, rhCC10, F-991, thymopentin, r(m)CRP, liver-selective insulin, subarin, L19-IL-2 fusion protein, elafin, NMK-150, ALTU-139, EN-12 2004, rhTPO, thrombopoietin receptor agonist, AL-108, AL-208, nerve growth factor antagonist, SLV-317, CGX-1007, INNO-105, teriparatide (Eligen), GEM-OS1, AC-162352, PRX-302, LFn-p24 fusion, EP-1043, gpE1, gpE2, MF-59, hPTH(1-34), 768974, SYN-101, PGN-0052, aviscumin, BIM-23190, multi-epitope tyrosinase peptide, encastim, APC-8024, GI-5005, ACC-001, TTS-CD3, vascular targeted TNF, desmopressin, onercept, and TP-9201.
[0096] In some embodiments, the polypeptide is adalimumab (Humira), infliximab (Remicade™), rituximab (Rituxan™ / MabThera™), etanercept (Enbrel™), bevacizumab (Avastin™), trastuzumab (Herceptin™), pegfilgrastim (Neulasta™), or any other suitable polypeptide, including biosimilars and biobetters.
[0097] Other suitable polypeptides are those listed below and in Table 1 of U.S. Patent Application Publication No. 2016 / 0097074. [Table 1-1] [Table 1-2] [Table 1-3]
[0098] In embodiments, the polypeptide is a hormone, a clotting / coagulation factor, a cytokine / growth factor, an antibody molecule, a fusion protein, a protein vaccine, or a peptide as shown in Table 2.
[0099] Representative recombinant products that can be produced using the methods described herein include, but are not limited to, those provided in the table below.
[0100] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4]
[0101] In an embodiment, the protein is a multispecific protein, for example a bispecific antibody as shown in Table 3.
[0102] [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6]
[0103] In an embodiment, the product is a polypeptide listed in Table 4.
[0104] [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6]
[0105] In some embodiments, the polypeptide is an antigen expressed by a cancer cell. In some embodiments, the recombinant or therapeutic polypeptide is a tumor-associated or tumor-specific antigen. In some embodiments, the recombinant or therapeutic polypeptide is an antigen that is an antigen that is an antigen associated with or specific to HER2, CD20, 9-O-acetyl-GD3, βhCG, A33 antigen, CA19-9 marker, CA-125 marker, calreticulin, carboanhydrase IX (MN / CA IX), CCR5, CCR8, CD19, CD22, CD25, CD27, CD30, CD33, CD38, CD44v6, CD63, CD70, CC123, CD138, carcinoembryonic antigen (CEA; CD66e), desmoglein 4, E-cadherin neoepitope, endosialin, ephrin A2 (EphA2), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), ErbB2, fetal acetylcholine receptor, fibroblast activation antigen (FAP), fucosyl GM1, GD2, GD3, GM2, ganglioside GD3, Globo H, glycoprotein 100, HER2 / neu, HER3, HER4, insulin-like growth factor receptor 1, Lewis-Y, LG, Ly-6, melanoma-specific chondroitin sulfate proteoglycan (MCSCP), mesothelin, MUCl, MUC2, MUC3, MUC4, MUC5 AC , MUC5 B , MUC7, MUC16, Mullerian inhibitory substance (MIS) receptor type II, plasma cell antigen, polySA, PSCA, PSMA, sonic hedgehog (SHH), SAS, STEAP, sTn antigen, TNF-alpha precursor, and combinations thereof.
[0106] In some embodiments, the polypeptide is an activating receptor, such as 2B4 (CD244), alpha4beta1 integrin, beta2 integrin, CD2, CD16, CD27, CD38, CD96, CD100, CD160, CD137, CEACAMl (CD66), CRTAM, CSl (CD319), DNAM-1 (CD226), GITR (TNFRSF18), activating KIR, NKG2C, NKG2D, NKG2 E, one or more natural cytotoxicity receptors, NTB-A, PEN-5, and combinations thereof; optionally, the β2 integrin comprises CD11a-CD18, CD11b-CD18, or CD11c-CD18; optionally, the activating KIR comprises KIR2DS1, KIR2DS4, or KIR-S; and optionally, the natural cytotoxicity receptor comprises NKp30, NKp44, NKp46, or NKp80.
[0107] In some embodiments, the polypeptide is an inhibitory receptor and is selected from KIR, ILT2 / LIR-1 / CD85j, inhibitory KIR, KLRG1, LAIR-1, NKG2A, NKR-P1A, Siglec-3, Siglec-7, Siglec-9, and combinations thereof, optionally wherein the inhibitory KIR comprises KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, KIR3DL2, or KIR-L.
[0108] In some embodiments, the polypeptide is an activating receptor, such as CD3, CD2 (LFA2, OX34), CD5, CD27 (TNFRSF7), CD28, CD30 (TNFRSF8), CD40L, CD84 (SLAMF5), CD137 (4-1BB), CD226, CD229 (Ly9, SLAMF3), CD244 (2B4, SLAMF4), CD319 (CRACC, BLAME), CD3 52 (Ly108, NTBA, SLAMF6), CRTAM (CD355), DR3 (TNFRSF25), GITR (CD357), HVEM (CD270), ICOS, LIGHT, LTβR (TNFRSF3), OX40 (CD134), NKG2D, SLAM (CD150, SLAMF1), TCRα, TCRβ, TCRδγ, TIM1 (HAVCR, KIM1), and combinations thereof.
[0109] In some embodiments, the polypeptide is an inhibitory receptor and is selected from PD-1 (CD279), 2B4 (CD244, SLAMF4), B71 (CD80), B7H1 (CD274, PD-L1), BTLA (CD272), CD160 (BY55, NK28), CD352 (Ly108, NTBA, SLAMF6), CD358 (DR6), CTLA-4 (CD152), LAG3, LAIR1, PD-1H (VISTA), TIGIT (VSIG9, VSTM3), TIM2 (TIMD2), TIM3 (HAVCR2, KIM3), and combinations thereof.
[0110] Exemplary other proteins include, but are not limited to, any of the proteins listed in Tables 1-10 of Leader et al., Protein therapeutics: a summary and pharmacological classification, Nature Reviews Drug Discovery, 2008, 7:21-39 (herein incorporated by reference); or any conjugate, variant, analog, or functional fragment of the recombinant polypeptides described herein.
[0111] Other recombinant protein products include, but are not limited to, non-antibody or alternative protein scaffolds, such as DARPins, affibodies and adnectins, which can be engineered to recognize or bind one or two or more, e.g., 1, 2, 3, 4 or 5 or more, different targets or antigens.
[0112] In one embodiment, a vector comprising a nucleic acid sequence encoding a product, e.g., a polypeptide, e.g., a recombinant polypeptide, described herein, further comprises a nucleic acid sequence encoding a selection marker. In one embodiment, the selection marker comprises glutamine synthetase (GS); dihydrofolate reductase (DHFR), e.g., an enzyme that confers resistance to methotrexate (MTX); proline or an antibiotic marker, e.g., an enzyme that confers resistance to antibiotics such as hygromycin, neomycin (G418), zeocin, puromycin, or blasticidin. In another embodiment, the selection marker comprises or is compatible with the Selexis selection system (e.g., SUREtechnology Platform™ and Selexis Genetic Elements™, commercially available from Selexis SA) or the Catalant selection system.
[0113] In one embodiment, a vector containing a nucleic acid sequence encoding a recombinant product described herein contains a selectable marker useful for identifying a cell or cells that contain a nucleic acid encoding a recombinant product described herein. In another embodiment, the selectable marker is useful for identifying a cell or cells that contain integration of a nucleic acid sequence encoding a recombinant product into their genome as described herein. Identification of a cell or cells that has integrated a nucleic acid sequence encoding a recombinant protein can be useful for selecting and genetically engineering cells or cell lines that stably express the product.
[0114] In one embodiment, the product differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid residues from a polypeptide of Tables 1-4. In another embodiment, the product differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 15% of its amino acid residues from a polypeptide of Table 2 or Table 3. Methods for determining percent identity are discussed above.
[0115] Other recombinant products include non-antibody scaffolds or alternative protein scaffolds, such as, but not limited to, DARPins, affibodies and adnectins.
[0116] Other exemplary therapeutic or diagnostic proteins include, but are not limited to, any of the proteins described in Tables 1-10 of Leader et al., "Protein therapeutics: a summary and pharmacological classification," Nature Reviews Drug Discovery, 2008, 7:21-39, and Walsh, "Biopharmaceutical benchmarks 2014," Nature Biotechnology, 2014, 32:992-1000, each of which is incorporated herein by reference; or any conjugate, variant, analog, or functional fragment of the recombinant polypeptides described herein.
[0117] Oxidation and Reduction Reduction and oxidation reactions (redox reactions), in which electrons are donated or removed from a compound, are common in biological systems. The tendency to donate or gain electrons in a redox reaction under set conditions can be described by the redox potential of the compound. The redox potential (ΔE) is measured in volts (V) or millivolts (mV). Redox potentials can be calculated for individual compounds, such as proteins, in which case the redox potential describes the affinity of the compound for electrons; the more positive the redox potential, the greater the tendency to gain electrons, and the more negative the redox potential, the greater the tendency to donate electrons. In addition to compounds, solutions, organelles, and cells can also have their tendency to gain or lose electrons, which is expressed as redox potential.
[0118] Cells use several systems to regulate their redox potential. The thioredoxin system in humans contains two proteins, Trx1 and Trx2. Trx proteins have a low redox potential and reduce disulfide bonds in proteins, and this reduction reaction is catalyzed by thioredoxin reductase (TrxR), which uses electrons from NADPH. Trx-S2+NADPH+H + →Trx-(SH)2+NADP + Protein-S2 + Trx-(SH)2 → Protein-(SH)2 + Trx-S2 The glutaredoxin system is composed of glutaredoxin, glutathione, and NADPH-dependent glutathione reductase. The glutaredoxin system uses glutathione to reduce disulfide bonds in proteins, which are returned to their reduced state by consumption of NADPH. Glutaredoxin is a dithiol mechanism. R-S2+Grx-(SH)2→R-(SH)2+Grx-S2 Grx-S2+2GSH → Grx-(SH)2+GSSG Or, monothiol mechanism RS-SG+Grx(SH)2→R-SH+Grx-S-SG Grx-S-SG+GSH → Grx-(SH)2+GSSG The thiol groups of the protein are reduced by either
[0119] For further information on redox reactions, potentials, and methods of modulating or controlling redox reactions / potentials, see, e.g., Holmgren et al., Biochem Soc Trans. December 2005; 33(Pt6):1375-7; Nordberg and Arner, Free Radic Biol Med. December 1, 2001; 31(11):1287-312; Ghezzi P., Biochem Soc Trans. December 2005; 33(Pt6):1378-81; Ivarsson et al., Diabetes. July 2005; 54(7):2132-42; Sen, C.K., Biochem Pharmacol 55(11), 1747-1758, June 1, 1998; and May et al., J Biol. Chem. 1997 September 5;272(36):22607-10;Molteni, S. N. et al. (2004), "Glutathione limits Ero1-dependent oxidation in the endoplasmic reticulum", Journal of Biological Chemistry 279(31):32667-32673;Kojer, K. and J. Riemer (2014), "Balancing oxidative protein folding: The influences of reducing pathways on disulfide bond formation", Biochimica et Biophysica Acta-Proteins and Proteomics 1844(8):1383-1390;Hanschmann, E.-M.(2013), "Thioredoxins, Glutaredoxins, and Peroxiredoxins-Molecular Mechanisms and Health Significance:from Cofactors to Antioxidants to Redox Signaling", Antioxidants & Redox Signaling 19(13):1539-1605; Chakravarthi, S. et al. (2006), "The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress", EMBO Reports 7(3):271-275; Flohe, L. (2013), "The myth of the GSSG / GSH redox potential". (2007), "Stress on redox," FEBS Letters 581(19):3634-3640, each of which is incorporated herein by reference in its entirety.
[0120] The redox potential can be adjusted independently of the redox regulatory system used by the cell.For example, the redox potential of a compound, such as a product, such as a protein, can be adjusted by adjusting the level of oxygen in the solution.Increasing the level of oxygen in the solution, for example, making the solution favorable for oxidation, increases the redox potential of the product, such as a protein.Increasing the redox potential of a product, such as a protein, can reduce the possibility that the disulfide bond of the product, such as a protein, is reduced, relative to a product, such as a protein, with a lower redox potential.
[0121] Application of production The methods of preparation of products, e.g., product variants, disclosed herein can be used to produce different products, to evaluate different cell lines, or to evaluate the products of different cell lines for use in bioreactors or processing vessels or tanks, or more generally with any source. The devices, facilities and methods described herein are suitable for culturing any desired cell line, including prokaryotic and / or eukaryotic cell lines. Furthermore, in embodiments, the devices, facilities and methods are suitable for culturing suspension cells or anchorage-dependent (adherent) cells, and are suitable for production operations configured for the production of pharmaceuticals and biopharmaceuticals, such as polypeptide products or cells, and / or for the production of viruses, such as those used in cell therapy and / or viral therapy.
[0122] As noted, in embodiments, the devices, facilities and methods allow for the production of eukaryotic cells, e.g., mammalian cells, or lower eukaryotic cells, e.g., yeast cells, filamentous fungal cells, or prokaryotic cells, e.g., gram-positive or gram-negative cells, and / or products of eukaryotic cells or prokaryotic cells, e.g., proteins, peptides, antibodies, amino acids, synthesized by eukaryotic cells in a large-scale manner. Unless otherwise stated herein, the devices, facilities and methods can include any desired quantity or production capacity, including, but not limited to, bench scale, pilot scale and commercial scale capabilities.
[0123] Also, unless otherwise stated herein, the devices, facilities and methods can include any suitable reactor(s), including, but not limited to, stirred tank, airlift, fiber, microfiber, hollow fiber, ceramic matrix, fluidized bed, fixed bed, and / or entrained bed bioreactors. As used herein, a "reactor" or "bioreactor" can include a fermenter or fermentation unit, or other reaction vessel, and the terms "reactor" and "bioreactor" are used interchangeably with "fermenter". For example, in some embodiments, a bioreactor unit can perform one or more, or all of the following functions: supplying nutrients and / or carbon sources, injecting appropriate gases (e.g., oxygen), inlet and outlet flows of fermentation or cell culture medium, separating gas and liquid phases, maintaining temperature, maintaining oxygen and CO2 levels, maintaining pH levels, agitation (e.g., stirring), and / or cleaning / sanitization. Examples of reactor units, such as fermentation units, may include multiple reactors within the unit, e.g., the unit may have 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 or more bioreactors in each unit, and / or the facility may include multiple units with a single reactor or multiple reactors within the facility. In various embodiments, the bioreactor may be suitable for batch, semi-fed-batch, fed-batch, perfusion, and / or continuous fermentation processes. Any suitable reactor diameter may be used. In embodiments, the bioreactor may have a volume between about 100 mL and about 50,000 L.Non-limiting examples include 100 mL, 250 mL, 500 mL, 750 mL, 1 liter, 2 liters, 3 liters, 4 liters, 5 liters, 6 liters, 7 liters, 8 liters, 9 liters, 10 liters, 15 liters, 20 liters, 25 liters, 30 liters, 40 liters, 50 liters, 60 liters, 70 liters, 80 liters, 90 liters, 100 liters, 150 liters, 200 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, Reactors may include reactors having volumes of 600 liters, 650 liters, 700 liters, 750 liters, 800 liters, 850 liters, 900 liters, 950 liters, 1000 liters, 1500 liters, 2000 liters, 2500 liters, 3000 liters, 3500 liters, 4000 liters, 4500 liters, 5000 liters, 6000 liters, 7000 liters, 8000 liters, 9000 liters, 10,000 liters, 15,000 liters, 20,000 liters, and / or 50,000 liters. In addition, suitable reactors may be multi-use, single-use, disposable, or non-disposable and may be formed of any suitable material, including metal alloys such as stainless steel (e.g., 316L or other suitable stainless steels) and Inconel, plastic, and / or glass. In some embodiments, suitable reactors may be circular, e.g., cylindrical. In some embodiments, a suitable reactor may be square, e.g., rectangular. In some cases, square reactors may offer advantages over circular reactors, such as ease of use (e.g., loading and setting up by one of ordinary skill in the art), greater mixing and uniformity of the reactor contents, and smaller floor footprint.
[0124] In embodiments, unless otherwise stated herein, the devices, facilities, and methods described herein for use in methods of making preparations may also include any suitable unit operations and / or equipment not otherwise mentioned, such as operations and / or equipment for separation, purification, and isolation of such products. Any suitable facilities and environments may be used, such as traditional field assembled facilities, modular, mobile and temporary facilities, or other suitable structures, facilities, and / or layouts. For example, in some embodiments, modular clean rooms may be used. Additionally, unless otherwise stated, the devices, systems, and methods described herein may be housed and / or function in a single location or facility, or may be housed and / or function in separate or multiple locations and / or facilities.
[0125] By way of non-limiting example, U.S. Patent Application Publication Nos. 2013 / 0280797; 2012 / 0077429; 2011 / 0280797; 2009 / 0305626; and U.S. Patent Nos. 8,298,054; 7,629,167; and 5,656,491, which are incorporated by reference herein in their entireties, describe examples of facilities, equipment, and / or systems that may be suitable.
[0126] Bioreactor setup and conditions In one aspect, the bioreactor of the disclosure or utilized by the methods of the disclosure is a single-use bioreactor.
[0127] The single-use bioreactor may include a bioprocess vessel, a shell, at least one agitator, at least one sparger, at least one gas filter inlet for the sparger(s) and headspace overlay, at least one inlet, at least one harvest port, at least one sample port, and at least one probe.
[0128] In one embodiment, the present disclosure is directed to a bioreactor including a bioprocess container. The bioprocess container is made from a liquid impermeable and flexible conformable material. For example, the bioprocess container can be made from a flexible film, such as a multi-layer film. In one embodiment, for example, the film includes a polyethylene polymer, such as low density polyethylene, that has been modified to form a hydrophilic surface. The hydrophilic surface is for contact with the cell culture in the bioreactor and improves wettability. In one embodiment, the polyethylene polymer is modified by being exposed to radiation, photo- or plasma-induced, or oxidation.
[0129] The bioprocess container can have a top, a bottom, and at least one sidewall therebetween. The bioprocess chamber can define a hollow housing for receiving a culture medium. The hollow housing can be in any of the following sizes: 100 mL, 250 mL, 500 mL, 750 mL, 1 liter, 2 liters, 3 liters, 4 liters, 5 liters, 6 liters, 7 liters, 8 liters, 9 liters, 10 liters, 15 liters, 20 liters, 25 liters, 30 liters, 40 liters, 50 liters, 60 liters, 70 liters, 80 liters, 90 liters, 100 liters, 150 liters, 200 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, 60 ...800 liters, 90 liters, 100 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, 600 liters, 800 liters, 90 liters, 100 liters, The fuel cell may have any suitable volume, such as 500 liters, 650 liters, 700 liters, 750 liters, 800 liters, 850 liters, 900 liters, 950 liters, 1000 liters, 1500 liters, 2000 liters, 2500 liters, 3000 liters, 3500 liters, 4000 liters, 4500 liters, 5000 liters, 6000 liters, 7000 liters, 8000 liters, 9000 liters, 10,000 liters, 15,000 liters, 20,000 liters and / or 50,000 liters.
[0130] The bioreactor can include at least one inlet for feeding material into the hollow housing of the bioprocess container. A mixing device including a rotatable shaft coupled with at least one agitator can extend into the hollow housing of the bioprocess container. In one embodiment, the rotatable shaft can be foldable. For example, the rotatable shaft can include at least one impeller made from a hydrophilic polymeric material that is foldable or collapsible towards the rotating shaft.
[0131] The bioreactor may also include at least one baffle configured to extend longitudinally adjacent to the sidewall of the bioprocess container. The baffle may have a shape that extends radially inward from the sidewall by an amount sufficient to affect the flow of fluid in the hollow enclosure during mixing of the culture medium by the mixing device. The baffle may be collapsible and / or foldable. In one embodiment, for example, the baffle may define an inflatable fluid bladder that allows the baffle to expand and contract. The baffle may be integral with the bioprocess container, meaning that the baffle is formed of a flexible, shape-forming material. Alternatively, the baffle may be separate from the bioprocess container. The baffle may be configured to be placed inside the hollow enclosure or may be placed outside the hollow enclosure. When placed outside the hollow enclosure, the sidewall of the bioprocess container fits around the shape of the baffle. For example, in one embodiment, the baffle may be removably attached to the outside of the metal shell. The bioprocess container may be placed in the metal shell to fit around the shape of the baffle. In one embodiment, the bioreactor can include about 2 to about 6 baffles spaced around the periphery of the hollow housing of the bioprocess container.
[0132] In one embodiment, the bioprocess container has a diameter and the one or more baffles extend radially inward a distance from about 3% to about 20%, for example, from about 5% to about 15% of the diameter of the bioprocess container.
[0133] The bioreactor can further include at least one sparger. For example, the sparger can include a ballast sparger including a gas tube having a longitudinal portion and a lateral portion. The longitudinal portion can extend vertically into the hollow housing of the bioprocess container, while the lateral portion can be located at the end of the longitudinal portion below the agitator. The lateral portion can define a plurality of holes for releasing gas into the culture medium contained within the bioprocess container. In one embodiment, the plurality of holes are drilled. The lateral portion can have any suitable shape. In one embodiment, the lateral portion can be configured to engage a rotatable shaft of the mixing device to stabilize the shaft. The rotatable shaft can extend to the lateral portion or can be housed within a shaft receiving member formed in the lateral portion.
[0134] In one embodiment, the bioreactor includes a first subsurface sparger and a second suprasegmental sparger. The holes in the subsurface sparger can be larger or smaller than the holes in the suprasegmental sparger. In one embodiment, the holes are drilled.
[0135] In one embodiment, the bioreactor can include at least one feed line extending into the hollow housing for supplying fluid to the bioprocess container. The feed line can include a subsurface fluid outlet located adjacent to the agitator. The fluid outlet can be associated with a fluid control device that only allows fluid to exit the fluid outlet and prevents fluid flow in the opposite direction. For example, the fluid control device can include a one-way valve.
[0136] In another embodiment, the bioreactor can include a feed line disposed on top of the bioprocess container. The feed line includes an upper surface fluid outlet disposed above the volume of culture medium present in the bioprocess container. The upper surface fluid outlet can be located such that fluid flowing through the fluid outlet directly contacts the culture medium contained within the bioprocess container. In one embodiment, the agitator can form a circumference as it rotates, and the upper surface fluid outlet of the feed line can be located above the circumference of the agitator such that fluid flowing through the fluid outlet contacts the culture medium within the circumference.
[0137] The bioreactor may be placed in operative association with a load cell to indicate collection of culture medium contained within the hollow housing. The bottom of the bioprocess container may have a dome shape to facilitate drainage. For example, the bioprocess container may include a drain line located at the bottom of the bioprocess container. The fluid collection device may be disposed intermediate the hollow housing of the bioprocess container and the drain line. The fluid collection device may have a shape configured to induce a vortex flow of fluid from the bioprocess container to the drain line. In one embodiment, the drain line has a cross-sectional area proportional to the volume of the hollow housing. For example, for purposes of illustration, the drain line may have a cross-sectional area of approximately 0.3 mm per liter of hollow housing volume. 2 From about 0.7 mm 2 For example, up to about 0.4 mm 2 From about 0.6 mm 2 The cross-sectional area may be up to 100 mm.
[0138] In one embodiment, the bioprocess container can include multiple ports for connecting to multiple supply lines for supplying fluids to the bioprocess container. Each port and corresponding supply line can include matching instructions to assist a user to connect the supply line to the respective port. For example, the matching instructions can include color, such that each port and corresponding supply line is color coded. Matching indications can also be applied to the supply lines and any corresponding ports, as well as the spargers and any corresponding connectors.
[0139] In one embodiment, the bioprocess container can include a port that includes a universal connector. The port can have a first end and a second end. The first end can be for forming a reconnectable attachment to a respective supply line. Each supply line can include a fluid filter disposed upstream of the corresponding port.
[0140] The present disclosure is also directed to a bioreactor system. The bioreactor system can include a bioprocess container made from a liquid-impermeable and flexible conformable material. The bioprocess container can have a top, a bottom, and at least one sidewall therebetween. The bioprocess chamber can define a hollow housing for receiving culture medium. The bioprocess container can also include multiple inlets for feeding materials into the hollow housing. A drain line can be disposed at the bottom of the bioprocess container for draining fluids. The mixing device can extend into the hollow housing of the bioprocess container and can include a rotatable shaft coupled with at least one agitator.
[0141] The bioreactor system may further include at least one sensor operatively associated with the bioprocess container for monitoring at least one parameter within the hollow enclosure. The at least one sensor may include a pH sensor, a dissolved carbon dioxide sensor, a dissolved oxygen sensor, a redox sensor, a load cell, a temperature sensor, or a tachometer. The controller may be disposed in communication with the at least one sensor. The controller may be configured to receive information from the at least one sensor and, based on the information, control a fluid supply to vary a flow rate of fluid from the fluid supply of the bioprocess container to the hollow enclosure to maintain at least one parameter of the culture medium contained within the hollow enclosure within preset limits.
[0142] For example, in one embodiment, the bioreactor system can include a carbon dioxide gas supplement in fluid communication with the bioprocess container and can also include a liquid alkali supplement in fluid communication with the bioprocess container. The at least one sensor can include a pH sensor, and the controller can be configured to adjust the pH level of the culture medium within preset limits by selectively adding an amount of carbon dioxide gas from the carbon dioxide gas supplement to lower the pH, or by selectively adding an amount of alkali from the liquid alkali supplement to increase the pH. In one embodiment, the system can include a first pH sensor and a second pH sensor, both in communication with the controller.
[0143] In yet another embodiment, the bioreactor system can include an oxygen gas supplement and the at least one sensor can include a dissolved oxygen sensor. The controller can regulate the dissolved oxygen level in the culture medium within preset limits by periodically adding an amount of oxygen gas from the oxygen gas supplement to the culture medium based on information received from the dissolved oxygen sensor.
[0144] In yet another embodiment, the bioreactor system can include a carbon dioxide gas supplement and the at least one sensor can include a dissolved carbon dioxide sensor. The controller can be configured to regulate the dissolved carbon dioxide level in the culture medium within preset limits by periodically adding an amount of carbon dioxide gas from the carbon dioxide gas supplement to the culture medium based on information received from the dissolved carbon dioxide sensor.
[0145] In yet another embodiment, the bioreactor system can include a thermal jacket surrounding the bioprocess container. The thermal jacket can be in fluid communication with at least one heated or cooled fluid. The bioreactor system can further include a temperature sensor for sensing a temperature of a culture medium contained within the bioprocess container. The temperature sensor can be in communication with the controller. The controller can be configured to receive information from the temperature sensor and, based on the information, control a flow of fluid to the thermal jacket to increase or decrease a temperature of the culture medium contained within the bioprocess container to maintain the culture medium within preset temperature limits.
[0146] In another embodiment, the bioreactor system can further include a tachometer for monitoring a rotational speed of a rotatable shaft coupled to the at least one agitator. The tachometer can be in communication with the controller. The controller can be in communication with a motor that rotates the shaft. The controller can be configured to control the motor in a manner that rotates the shaft at a predetermined speed based on information received from the tachometer.
[0147] The controller may include one or more microprocessors.
[0148] In one embodiment, the controller can be configured to receive information from multiple sensors to control multiple parameters within the bioreactor.
[0149] In one embodiment, the one or more sensors described above can be incorporated into the bioprocess container and can be disposable with the bioprocess container.
[0150] The present disclosure is also directed to a bioreactor including a bioprocess container made from a liquid impermeable and flexible conformable material. The bioprocess container can have a top, a bottom, and at least one sidewall therebetween. The bioprocess chamber can define a hollow housing for receiving a culture medium. At least one supply line can extend into the hollow housing for supplying a fluid to the bioprocess container.
[0151] In one embodiment, the feed line includes a subsurface fluid outlet located adjacent to the agitator. The fluid outlet can be associated with a fluid control device that only allows fluid to flow out of the fluid outlet and prevents fluid flow in the opposite direction.
[0152] In an alternative embodiment, the feed line may include an upper surface fluid outlet disposed above the volume of culture medium present in the bioprocess container. The upper surface fluid outlet may be positioned such that fluid flowing through the fluid outlet is in direct contact with the culture medium contained within the bioprocess container without contacting the sidewalls.
[0153] In one embodiment, the bioreactor can include a first feed line that includes a subsurface fluid outlet and a second feed line that includes an above-surface fluid outlet, hi one embodiment, the bioreactor can include from about 1 to about 5, e.g., from about 2 to about 3, feed lines with above-surface fluid outlets.
[0154] In yet another embodiment, the present disclosure is directed to a method for creating a single-use bioreactor. The method includes constructing a bioprocess container from a liquid-impermeable and flexible conformable material. The bioprocess container has a top, a bottom, and at least one sidewall therebetween. The bioprocess chamber defines a hollow housing for receiving a culture medium. The hollow housing can have a volume of about 1-250 milliliters, 250 milliliters to 50 liters, 50 liters to 800 liters, or 800-200,000 liters. The bioprocess container includes a plurality of inlets for feeding materials into the hollow housing of the bioprocess container. Each inlet has a diameter.
[0155] A mixing device is inserted into the hollow housing. The mixing device includes a rotatable shaft coupled to at least one agitator. At least one sparger is also inserted into the hollow housing of the bioprocess container. The sparger includes a gas tube having a longitudinal portion and a lateral portion. The longitudinal portion extends vertically into the hollow housing. The lateral portion is located at the end of the longitudinal portion below the agitator. The lateral portion defines a plurality of holes for releasing gas into a culture medium contained within the bioprocess container. The plurality of holes has a diameter.
[0156] The drain line is connected to the bottom of the bioprocess container, the drain line having a cross-sectional area.
[0157] According to the present disclosure, the diameter of the inlet, the diameter of the sparger holes, and the cross-sectional area of the drain line are proportional to the volume of the hollow housing. For example, the drain line has a cross-sectional area of approximately 0.3 mm per liter of hollow housing volume. 2 From about 0.7 mm 2 The cross-sectional area may be up to 100 mm.
[0158] The present disclosure is also directed to a bioreactor including a bioprocess container made from a liquid impermeable and flexible conformable material. The bioprocess chamber can define a hollow housing for receiving a culture medium and can include at least one inlet. A mixing device including a rotatable shaft coupled with a plurality of agitators can extend into the hollow housing of the bioprocess container.
[0159] According to the present disclosure, the bioreactor may further include a cell retention chamber in fluid communication with the hollow housing of the bioprocess container. A filtrate outlet may be placed in fluid communication with the cell retention chamber. The filtrate outlet includes a biofilter that is permeable to liquids but impermeable to biological material contained in the culture medium. The filtrate outlet is for continuously or periodically removing liquids from the cell retention chamber. The flow regulator is configured to alternate the flow rate of the culture medium between the hollow housing of the bioprocess container and the cell retention chamber for performing a perfusion process.
[0160] For example, the flow regulator can be in communication with a pressurized gas source and a vacuum source and can be configured to alternately apply vacuum or gas pressure to a fluid contained in the cell retention chamber to recirculate the fluid back and forth between the hollow enclosure of the bioprocess container and the cell retention chamber.
[0161] In one embodiment, the flow regulator valve can include a reciprocating diaphragm that alternates between applying pressure and applying suction to the fluid contained in the cell retention chamber.
[0162] The present disclosure is also directed to a bioreactor including a bioprocess container made from a liquid-impermeable and flexible conformable material. The bioprocess chamber defines a hollow housing for receiving a culture medium. A mixing device including a rotatable shaft coupled with at least one agitator can extend into the hollow housing of the bioprocess container. According to the present disclosure, the agitator can be foldable on the rotating shaft. For example, the agitator can include an impeller including at least one blade element. The blade element can be foldable towards the rotatable shaft. In one embodiment, the rotatable shaft is coupled with a first impeller and a second impeller, both impellers can include at least one foldable blade element. A retaining ring can be disposed on the shaft. The retaining ring can include an agitator-engaged position and an agitator-disengaged position for holding the agitator in an upright position during mixing or in a collapsed position and a collapsed position, respectively.
[0163] In one embodiment, the rotatable shaft includes a metal stiffener bar surrounded by a shaft sleeve. The metal stiffener bar, which may be made of stainless steel, may be made of multiple pieces attached together. The top of the stiffener bar may include a magnetic member that magnetically engages with the motor. The shaft sleeve may be constructed of a polymeric material. The agitator on the shaft may also be made of a polymeric material, such as a hydrophilic polymer. For example, the shaft sleeve and agitator may include a polyethylene polymer that has been modified by being subjected to radiation, light or plasma induction, or oxidation.
[0164] In one embodiment, a single-use bioreactor system according to the present disclosure includes a single-use cell culture bioprocess container ("SUB"), a reusable shell that holds the SUB during operation, and a controller that controls the operation of the SUB and associated subsystems and processes. The associated subsystems include an agitation system, a baffle system, a sparger system, a feed system, a harvest system, a monitoring system, a control system(s), and an injection system.
[0165] In one embodiment, each of the cell culture in contact with the surface of the SUB and the process fluid in contact with the surface of the SUB is preferably free of animal-derived components.
[0166] According to one aspect of the present disclosure, a single-use bioreactor is provided. The single-use bioreactor may include a bioprocess vessel, a shell, at least one agitator, at least one sparger, at least one gas filter inlet for the sparger(s) and headspace overlay, at least one inlet, at least one harvest port, at least one sample port, and at least one probe.
[0167] The single-use bioreactor of the present disclosure may also be used with a single-use bioreactor (SUB) system, which may include a flexible bioreactor bioprocess vessel that is single-use and disposable, a SUB shell configured to hold the flexible bioreactor bioprocess vessel, an agitator, a sparger, multiple ports, and at least one controller configured to control multiple parameters associated with the SUB system such that the SUB system produces biomaterials corresponding to biomaterials that can be produced in a similarly sized stainless steel bioreactor.
[0168] According to the present disclosure, the rotatable shaft may be coupled with a top impeller and a bottom impeller. Both the top impeller and the bottom impeller may be made from a polymeric material. For example, in one embodiment, the impellers may be 3D printed. Both the top impeller and the bottom impeller may define a hydrophilic surface. For example, the polymeric material used to form the impellers may include a hydrophilic polymer or may include a polymer that has been surface-modified to make the surface hydrophilic.
[0169] In one embodiment, for example, the top and bottom impellers are made from a polyolefin polymer, such as polyethylene or polypropylene. In one embodiment, low density polyethylene can be used. Low density polyethylene can be modified by being subjected to irradiation, light or plasma induction, or oxidation to form a hydrophilic surface.
[0170] The top impeller may comprise a hydrofoil impeller, while the bottom impeller may comprise a four pitch blade high solidity impeller. The ratio of the impeller to the tank diameter may be from about 0.35 to about 0.55, such as from about 0.44 to about 0.46. The top and bottom impellers may have a power number (N p ) and a flow rate number (N q ).
[0171] In some embodiments, the bioreactor of the present disclosure is a bioreactor described in U.S. Patent No. 9,670,446, the contents of which are incorporated herein by reference in their entirety. In some embodiments, the bioreactor of the present disclosure includes portions or features of the bioreactor described in U.S. Patent No. 9,670,446.
[0172] In one embodiment, the bioreactor may be operatively connected to a harvest vessel. The harvest vessel may include a means for mixing the culture and gas (e.g., for aerating the culture), for example, to ensure proper oxygenation of the culture. In one embodiment, the harvest vessel includes a headspace that includes the supernatant, e.g., accumulated in the harvest vessel from the bioreactor, and a gas, e.g., air, oxygen, or a mixture of air and oxygen. In one embodiment, the harvest vessel uses surface aeration to oxygenate the culture supernatant with the gas in the headspace, e.g., air or oxygen, or a gas mixture of air and oxygen. Surface aeration involves a cascading or flow of the supernatant from the J-tube inlet down the wall of the harvest vessel and from the liquid surface of the supernatant in contact with the headspace. In some embodiments, the movement or cascading results in an increase in the oxygenation level of the culture.
[0173] The collection vessel may include at least one mixer, at least one gas filter inlet for headspace overlay, at least one inlet with an inner J-tube toward the vessel wall, at least one collection port, at least one sample port, at least one temperature probe, at least one redox probe, at least one DOT probe, and at least one pH probe, at least one temperature control, at least one gas flow, e.g., at least one air flow control and at least one O2 flow control. In one embodiment, the collection vessel contains a headspace gas mixture of air / O2 that maintains the DOT in the range of air saturation greater than 40% to air saturation up to 500%.
[0174] In one embodiment, the bioreactor or harvest vessel comprises a redox probe, for example an in-line redox probe, for example a Mettler Toledo in-line redox probe.
[0175] In some embodiments, the method comprises providing, e.g., adding, or adjusting, e.g., increasing or decreasing, the activity / abundance of a component of the thioredoxin or glutathione / glutaredoxin system to provide or maintain a redox potential in the culture or cells or culture supernatant of the culture, and the bioreactor or harvest vessel is capable of providing, e.g., adding, or adjusting, e.g., increasing or decreasing, the activity / abundance of a component of the thioredoxin or glutathione / glutaredoxin system to provide or maintain a redox potential in the culture or cells or culture supernatant of the culture. Thioredoxin and glutathione / glutaredoxin systems and their components are known in the art. See, e.g., Holmgren et al., Biochem Soc Trans. 2005 December; 33(Pt6):1375-7; Nordberg and Arner., Free Radic Biol Med. 2001 December 1; 31(11):1287-312; Ghezzi P., Biochem Soc Trans. 2005 December; 33(Pt6):1378-81; Ivarsson et al., Diabetes. 2005 July; 54(7):2132-42; Sen, CK., Biochem Pharmacol 55(11), 1747-1758, June 1, 1998; and May et al., J Biol. Chem. 1997 Sep. 5;272(36):22607-10, the contents of which are incorporated herein by reference in their entireties.
[0176] In one embodiment, the method includes a step of providing, e.g., adding, or adjusting, e.g., increasing or decreasing, the activity / abundance of GILT (gamma-interferon-inducible lysosomal thiol reductase), or the bioreactor or collection vessel is capable of providing, e.g., adding, or adjusting, e.g., increasing or decreasing, the activity / abundance of GILT (gamma-interferon-inducible lysosomal thiol reductase). See, e.g., Rausch and Hastings., Mol Immunol. 2015 December; 68(2Pt A):124-8. doi:10.1016 / j.molimm.2015.06.008. Epub 2015 June 23; and Hastings and Cresswell., Antioxid Redox Signal. 2011 August 1; 15(3):657-668, the contents of which are incorporated by reference herein in their entireties. In one embodiment, the method includes providing, e.g., adding, to the growth culture, or the bioreactor or harvest vessel is capable of providing, e.g., adding, to the growth culture, ascorbic acid, dehydroascorbic acid, or an ascorbic acid or dehydroascorbic acid modifying component. The redox potential modulating properties of ascorbic acid and dehydroascorbic acid are known in the art. See, e.g., Winkler et al., Free Radic Biol Med. 1994 Oct;17(4):333-49, which is incorporated herein by reference in its entirety.
[0177] In one embodiment, the method includes providing an intracellular agent to the production culture, e.g., adding a redox potential-indicating label, e.g., a redox-sensitive dye or molecular probe, or the bioreactor is capable of providing an intracellular agent to the production culture, e.g., adding a redox potential-indicating label, e.g., a redox-sensitive dye or molecular probe. Such redox potential-indicating labels may be useful for monitoring the redox potential of the culture or cells within the culture. Redox potential-indicating labels include 2,2'-bipyridine (Ru complex), nitrophenanthroline (Fe complex), N-phenylanthranilic acid, 1,10-phenanthroline iron (II) sulfate complex (ferroin), N-ethoxychrysoidine, 2,2'-bipyridine (Fe complex), 5,6-dimethylphenanthroline (Fe complex), o-dianisidine, sodium diphenylamine sulfonate, diphenylbenzidine, diphenylamine, viologen, 2,6-dibromophenol-indophenol, ... In addition, the labels disclosed in any of the references incorporated herein include, but are not limited to, indophenol sodium, 2,6-dichlorophenol-indophenol sodium, o-cresol indophenol sodium, thionine (Lautz violet), methylene blue, indigo tetrasulfonic acid, indigo trisulfonic acid, indigo carmine (indigo disulfonic acid), indigo monosulfonic acid, phenosafranin, safranine, neutral red, the labels disclosed in any of the references incorporated herein, and the labels disclosed in Schwarzlander M et al., Antioxid Redox Signal, 2016 May 1;24(13):680-712, which are incorporated herein by reference in their entirety.
[0178] In another embodiment, the method includes providing the production culture with an extracellular agent, e.g., a metabolite, a transition state metal ion, as described herein, or the bioreactor or harvest vessel is capable of providing the production culture with an extracellular agent, e.g., a metabolite, a transition state metal ion, as described herein.
[0179] In some embodiments, a bioreactor, or a bioreactor for use in the methods of the present disclosure, can be set up according to the following principles. - The functional settings of the bioreactor during harvesting of the production culture are important to ensure that the culture leaving the bioreactor is well oxygenated and carries dissolved oxygen to the next processing step. Once the cell culture reaches the target temperature for starting the harvesting step, ensure that all process controls that may be antagonistic to the oxygenation of the production culture are inhibited. These may include inhibiting the sparge nitrogen gas flow, if enabled, inhibiting the on-demand CO2 gas flow control, if enabled, inhibiting the on-demand alkali control, if enabled, and inhibiting the application of feed, if enabled.
[0180] - A nitrogen sparge gas stream is usually used as a ballast to control the dissolved oxygen tension (DOT) at a set point when the cellular demand for oxygen is low, but it may be kept flowing actively during the course of the production phase. Nitrogen is also used in airlift bioreactors as a carrier ballast to maintain mixing in these vessels. However, when nitrogen sparge gas is used, it must be restrained to prevent dilution of the oxygen composition of the sparge gas used to aerate the production culture during the harvest step, so that the dissolved oxygen, DOT in the culture, does not reach 100% air saturation (if air-only sparge is used) or the maximum expected DOT (if a combination of air and oxygen is used). Thus, the sparge nitrogen limits the maximum expected dissolved oxygen concentration for a given air-only or air-oxygen mixture sparge. A CO2 gas stream is sparged into the production culture in response to an increase in process pH above the control range. If the CO2 gas stream sparge is vigorous, it dilutes the oxygen composition of the sparge gas, which in turn limits the maximum dissolved oxygen concentration expected for a given air-only or air-oxygen mixture sparge. Thus, this inactivation during production culture harvest prevents dilution of the aerating sparge gas.
[0181] - Addition of alkaline solution to the production culture in response to a drop in the process pH below the control range is necessary for tight pH control during the cultivation of the production culture. However, due to the continuous reduction in the working volume and the overdosing of alkaline solution, there is a potential risk of increased cell injury and cell death due to the application of alkaline solution while the production culture is harvested. Application of feed into the production culture is necessary while the culture is actively growing and metabolizing. However, the continuous reduction in the working volume during harvest affects the mixing behavior of the bioreactor, leading to increased cell injury and cell death due to the application of the feed solution due to the non-physiological nature of the feed (high osmolarity and high or low pH) and the microenvironment that occurs in the vessel with poor mixing.
[0182] - Once the production culture reaches the target temperature for starting the harvest step, ensure that all process controls that may facilitate oxygenation of the production culture are enabled. These may include enabling sparge air and / or oxygen gas flow, if not enabled, enabling headspace air and / or oxygen flow, if not enabled, and finally enabling headspace pressure, if not enabled. The on-demand air and / or oxygen sparge flow may be very low and may be stopped once the production culture stops growing or cools for harvest. The continuous application of air and oxygen sparge at various continuous fixed flow rates is critical to the oxygenation of the production culture and to ensure that the production culture delivers dissolved oxygen to the cells, the clarification filter housing or centrifuge, and the flow path between the bioreactor and the filter housing or centrifuge, and the flow path between the filter housing or centrifuge and the supernatant collection vessel (e.g., harvest vessel). Headspace or overlay aeration is typically in effect during cultivation of the production culture to ensure that the headspace of the bioreactor is continually purged with metabolic CO2 gas. Continuous overlay aeration of the production culture during harvest avoids bubble formation and promotes oxygenation of the culture surface while the production culture is discharged from the bioreactor, albeit more slowly than is achieved with sparge gas.
[0183] - For bioreactors capable of operating with headspace pressure, where pressure is used during the cultivation of the production culture to aid in increasing the solubility of gases in the liquid phase (culture) or to maintain a positive pressure in the bioreactor to prevent the ingress of environmental contaminants beyond the sterile boundary of the vessel, it is recommended to maintain pressure during the harvest. In fact, when the harvest is driven by pressure, the oxygenation of the culture is aided if the gas used to pressurize the bioreactor is air or a mixed blend of air and oxygen. However, when the harvest is driven by a pump, typically no headspace pressure is used. The use of headspace pressure with air or an air / oxygen gas mixture in such a situation is beneficial to aid in the oxygenation of the culture and for the harvest tubing to withstand collapse under the suction head upstream of the pump head when the culture flows as fast as required for the scale of operation required during the harvest operation.
[0184] - For single-use bioreactors, the design of the harvest line in terms of internal perforation size and wall strength to withstand collapse under the suction occurring upstream of the pump head at high flow rates is important to ensure that the harvest flow rate is not impeded by tubing blockage. The effects of tubing blockage can not only limit the harvest flow rate, but also promote increased cell death and cell lysis, as well as outgassing of dissolved oxygen from the culture. The effects of tubing blockage include possible exposure of cells and product to a low / oxygen-depleted environment in the filter housing due to increased residence time in the housing at slow flow rates, possible promotion of release of intracellular factors due to increased cell death and cell lysis passing through the collapsed opening, as well as possible outgassing in the suction zone and removal of dissolved oxygen from the culture due to the smaller amount of dissolved oxygen carried by the culture into the filter housing. In one embodiment, the method disclosed herein avoids these negative effects on product stability.
[0185] The choice of inner diameter of the collection tube and the pump used will determine the volumetric throughput of the process (liters of process supernatant per filter area, L / m) for the cell clarification step by the depth filter or a centrifuge coupled to a depth filter. 2 ) is selected to achieve the flow rate required to achieve the required flow rate at the suction head upstream of the pump head. The material of construction of the recovery line must be rigid enough to withstand the crushing forces at the suction head occurring upstream of the pump head. Materials other than the commonly used platinum cured silicone or C-flex are suggested for the construction of the recovery tube. As an alternative to the commonly used materials, the use of braided tubing may be considered.
[0186] - In some embodiments, the method includes optimizing the depth filter area to avoid filter fouling and blockage during the filter clarification step, or the bioreactor is capable of optimizing the depth filter area to avoid filter fouling and blockage during the filter clarification step, whereby minimizing the residence time of the cell culture in the filter housing is an essential step to ensure oxygenation of the production culture and dissolved oxygen, which is carried out of the bioreactor, is not exhausted while the culture flows and resides in the filter housing before being discharged as supernatant. Furthermore, the flow rate must be adequate to minimize the residence time of the supernatant between the clarification step (filter housing) and the supernatant collection vessel (e.g., harvest vessel).
[0187] The area of the cell clarification filters (primary, secondary and tertiary) is determined by the required volumetric throughput of the process and the flux (L / m 2The filter area and filter type selected for optimal cell clarification must avoid higher pressure differences between different filter stages, which represents filter fouling and impending filter blockage. It is therefore expected that a reduction in flux across different serially connected filters will result in an increase in residence time in the filter housing, resulting in increased consumption / depletion of dissolved oxygen in the supernatant in the filter housing, which results in hypoxia in the supernatant. The increase in higher pressure differences between the primary and secondary stage filters is also problematic because it promotes higher cell lysis and release of intracellular factors that destabilize the product when activated.
[0188] - in some embodiments, the method includes or the bioreactor is capable of ensuring that the cell-free supernatant is collected in a well-aerated and mixed collection vessel (steel or single use), which is designed to ensure that the cell-free supernatant is collected in a well-aerated and mixed collection vessel (steel or single use), by impinging the collected filtrate on the vessel wall surface by designing an internal nozzle directed towards the vessel wall, which forces the filtrate to cascade down the vessel wall; and / or by the ability to fill the collection vessel with a gaseous environment composed of air or any given combination of air and oxygen, prior to collection of the filtrate, in order to promote oxygenation of the collected filtrate to more than >40% air saturation and ≦500% air saturation.
[0189] In one embodiment, the collection vessel is a stainless steel collection vessel. The method of supernatant collection and the design of the collection vessel are the final elements of the approach to protect the product during the collection step. Currently, the collected supernatant is collected in a jacketed stainless steel vessel with a mixer to continuously mix the collected supernatant. The collected supernatant is discharged into the collection vessel through a headspace port with an internal "J" tube that directs the flow of the supernatant on the vessel wall from where it cascades down the wall to collect at the bottom of the tank. Additionally, these stainless steel vessels are filled with sterile air to keep the vessel pressurized above atmospheric pressure after steam-implemented sterilization has been performed to prevent the ingress of environmental contaminants beyond the vessel's sterile boundary. It is assumed that the collected supernatant in these vessels is oxygenated as it cascades down the vessel wall under a pressurized air atmosphere. Further oxygenation of the supernatant occurs through contact of the headspace above the collected supernatant with surfaces.
[0190] In another embodiment, the collection vessel is a single-use collection vessel. The single-use supernatant collection vessel is a gamma-irradiated, evacuated bag. During collection of the supernatant, the bag is filled and replaced with a vacuum, so that no gas headspace is created above the collected supernatant. These bags do not have an agitator, so the collected supernatant cannot be mixed, and the bag is inserted into an unjacketed plastic or stainless steel shell, which does not allow the collected supernatant to be heated or cooled. Once the bag is filled with the supernatant, it is transferred to a +5°C storage location for up to 14 days. The purification process may begin with a primary capture step immediately after collection or within the 14-day holding period.
[0191] The approach to ensure oxygenation of the production culture is maintained at a DOT ranging from greater than 40% air saturation to less than 500% air saturation during the harvest step with the intention of "loading" the production culture with dissolved oxygen that is expected to be carried through and throughout the clarification step so that when the supernatant is harvested it has enough dissolved oxygen to prevent activation of cellular factors that may promote product dissociation. The harvest vessel is designed to ensure that the harvested supernatant remains well oxygenated while held under +5°C storage for up to 14 days. This is achieved by a vessel design that ensures that the supernatant remains oxygenated while harvested and held under +5°C storage, for example by surface aeration. In one embodiment, the design of the harvest vessel includes the following features: - The container or single-use bag has an agitator / mixer that provides sufficient axial bulk mixing to allow the collected supernatant to be oxygenated by surface aeration.
[0192] - The container or the shell of the single-use bag is jacketed with a suitably sized thermal cycling device that allows the temperature of the contents of the container to reach +5°C, for example from room temperature within 4 hours, and to heat from +5°C to room temperature within a similar time.
[0193] - The container or shell of the single-use bag is fitted with appropriately sized air and oxygen gas flow controllers that allow the headspace to be ventilated with air, oxygen, or oxygen-enriched gas.
[0194] - The vessels or single-use bags and shells are fitted with overlay gas filters suitable for air and oxygen gas at flow rates appropriate for the scale of operation, and exhaust gas vent filters suitable for air and oxygen gas at flow rates appropriate for the scale of operation, that allow a continuous flow of air and oxygen across the headspace to fill the collection vessel with a gaseous environment comprising air, or any given combination of air and oxygen, during collection of the supernatant filtrate and once collection is completed, to promote oxygenation of the supernatant filtrate to greater than >40% air saturation and ≦500% air saturation.
[0195] - The containers or single-use bags and shells are fitted with pressure sensors and safety interlocks that will shut off the headspace gas if the pressure exceeds safe limits for the scale of operation and container design.
[0196] - The vessels or single-use bags and shells are fitted with process sensor ports for pH, DOT, redox and temperature. The location of the probes within the vessel or bag allows for monitoring at the smallest operating volume appropriate to the scale of operation.
[0197] - The container or single-use bag is fitted with an addition spout at the top of the container which has a port fitted with an internal nozzle that directs the flow of liquid towards the container wall and encourages the liquid to cascade down the container wall.
[0198] Cells and cell culture In one aspect, the disclosure relates to methods and compositions for engineering or creating cells or cell lines that produce a product, e.g., a recombinant product, e.g., a stabilized product, e.g., a stabilized protein, as described herein. In another aspect, the disclosure relates to methods and compositions for engineering or creating cells or cell lines that have improved, e.g., reduced dissociation, improved productivity and / or product quality.
[0199] In an embodiment, the cell is a mammalian cell, or a non-mammalian cell, such as an insect cell, a yeast cell, a fungal cell, a plant cell, an archaeal cell, such as a cell from an archaeal species or a bacterial cell. In an embodiment, the cell is from a human, a mouse, a rat, a Chinese hamster, a Syrian hamster, a monkey, an ape, a dog, a duck, a horse, a parrot, a ferret, a fish or a cat. In an embodiment, the cell is an animal cell. In an embodiment, the cell is a mammalian cell, such as a human cell, or a rodent cell, such as a hamster cell, a mouse cell or a rat cell. In an embodiment, the cell is a prokaryotic cell, such as a bacterial cell. In an embodiment, the cell is a species of Actinobacteria, such as Mycobacterium tuberculosis.
[0200] In one embodiment, the cell is a Chinese Hamster Ovary (CHO) cell. In one embodiment, the cell is a CHO-K1 cell, a CHO-K1 SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knockout cell, a CHO FUT8 GS knockout cell, a CHOZN or a CHO derived cell. A CHO GS knockout cell (e.g., a GSKO cell) is, for example, a CHO-K1 SV GS knockout cell. A CHO FUT8 knockout cell is, for example, a Potelligent® CHOK1 SV (Lonza Biologics, Inc.).
[0201] In another embodiment, the cell is HeLa, HEK293, HT1080, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK (baby hamster kidney cells), VERO, SP2 / 0, NS0, YB2 / 0, Y0, EB66, C127, L cells, COS, e.g., COS1 and COS7, QC1-3, CHO-K1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DUXB11, and CHOZN, or any cell derived therefrom. In one embodiment, the cell is a stem cell. In one embodiment, the cell is any differentiated form of the cells described herein. In one embodiment, the cell is a cell derived from any primary cell in culture.
[0202] In one embodiment, the cell is any one of the cells described herein that produces a product, e.g., a product described herein. In one embodiment, the cell is any one of the cells described herein that comprises an exogenous nucleic acid encoding a recombinant polypeptide, e.g., expresses a recombinant polypolypeptide, e.g., a recombinant polypeptide selected from Table 2 or Table 3.
[0203] In one embodiment, the cell culture is performed as a batch culture, a fed-batch culture, a draw and fill culture, or a continuous culture. In one embodiment, the cell culture is an adherent culture. In one embodiment, the cell culture is a suspension culture. In one embodiment, the cell or cell culture is placed in vivo for expression of the recombinant polypeptide, for example, in a model organism or a human subject.
[0204] For example, the method is carried out in a large bioreactor, e.g., a bioreactor having at least two impellers, large bioreactor systems and methods for the cultivation and large scale growth of mammalian cells. In one embodiment, the bioreactor is a bioreactor as described in 2011 / 0312087.
[0205] In one embodiment, the cells are cultured in a bioreactor as disclosed in U.S. Patent Application No. 62 / 242,758, the contents of which are incorporated herein in their entirety. Disclosed therein are systems and methods for control of at least one bioreactor, other cell culture related equipment, and systems including any combination thereof. For example, systems and methods for control of a bioreactor may include control of multiple bioreactors and other types of culture related equipment, such as equipment for fermentation, harvesting, equipment for microfiltration and purification (e.g., liquid chromatography skid systems), buffer preparation, media preparation, etc. Multiple bioreactors and other types of culture related equipment may be located in a plant, and control of such equipment may be known as a plant-wide control system ("PWCS").
[0206] In one embodiment, the method is carried out in a manufacturing facility that offers both batch and continuous manufacturing using at least a portion of single-use disposable technology, such as that described in U.S. Patent Application No. 62 / 246,478, the contents of which are incorporated herein in their entirety. In one embodiment, the manufacturing facility is for the production of active pharmaceutical ingredients ("API").
[0207] Cooling can be accomplished using methods known in the art. For example, larger reactors typically have a water jacket through which thermostatic water is passed to control the temperature of the culture. In an embodiment, the cold water make-up of the process is delivered into the jacket to result in substantial and rapid cooling. In an embodiment, a cooling unit is used to remove heat. Cooling can be performed one or more times as desired when cooling the production culture during culturing (i.e., causing an increase in the number of cells or inducing production of a desired product from the cell culture), or at the end of the production phase, or when harvesting the cells. Since organisms have different optimal temperatures at which they grow, the cooling temperature is selected based on the relatively higher temperature of the step or steps preceding the cooling step. In an embodiment, cooling of the cultured cells is performed to reduce the oxygen consumption rate of the cells so that the harvest stream remains oxygenated throughout the harvest process.
[0208] For mammalian cell lines, the temperature change in the culture process is typically 27-35° C. (e.g., 27, 28, 29, 30, 31 or 32, 33, 34, or 35° C.). In some embodiments, the temperature is reduced to 30-33° C. after the exponential growth phase. Without wishing to be bound by theory, it is believed that reducing the temperature to 12-18° C., e.g., 15° C., after the production phase reduces the specific rate of oxygen consumption by a factor of 10.
[0209] In one embodiment, the culture medium is serum-free.
[0210] Other suitable media and culture methods for mammalian cell lines are well known in the art, for example, as described in US Pat. No. 5,633,162. Examples of standard cell culture media for laboratory flasks or low density cell cultures and adapted to the requirements of specific cell types are, for example, Roswell Park Memorial Institute (RPMI) 1640 medium (Morre, G., The Journal of the American Medical Association, vol. 199, p. 519f, 1967), L-15 medium (Leibovitz, A. et al., Amer. J. of Hygiene, vol. 78, p. 1, p. 173ff, 1963), Dulbecco's Modified Eagle's Medium (DMEM), Eagle's Minimum Essential Medium (MEM), Ham's F12 medium (Ham, R. et al., Proc. Natl. Acad. Sc. 53, p. 288ff, 1965) or Iscoves' Modified DMEM lacking albumin, transferrin and lecithin (Iscoves et al., J. Exp. med. 1, p. 923ff, 1978). For example, Ham's F10 medium or Ham's F12 medium have been specifically designed for CHO cell culture. Other media specifically adapted for CHO cell culture are described in EP 481791. Other suitable culture methods are known to those skilled in the art and may depend on the recombinant polypeptide product and the host cell used. It is within the skill of the art to determine or optimize suitable conditions for expression and production of a product, e.g., a recombinant polypeptide, expressed by a cell.
[0211] Assays for quantifying the amount, level or content of a product produced or secreted, e.g., in the culture medium, include protein quantification assays, e.g., Bradford protein assay, SDS-PAGE analysis, immunoblotting, e.g., Western blotting, and automated means, e.g., using a Nanodrop device. Other methods for measuring increased protein production are well known to those skilled in the art. For example, increased recombinant protein production may be determined on a small scale by measuring the concentration in tissue culture medium by ELISA (Smales et al., 2004, Biotechnology Bioengineering 88:474-488). It can also be quantitatively determined on a larger scale, e.g., by a ForteBio Octet for high-throughput measurement of recombinant monoclonal antibody (mAb) concentration in the medium (Mason et al., 2012, Biotechnology Progress 28:846-855) or by HPLC of Protein A (Stansfield et al., 2007, Biotechnology Bioengineering 97:410-424). Other methods for determining the production of a product, for example a recombinant polypeptide as described herein, can refer to the specific production rate (qP) of a product, in particular a recombinant polypeptide, in a cell, and / or the time integral of the viable cell concentration (IVC). In one embodiment, a method for determining the production comprises a combination of the determination of qP and IVC. The production or productivity of a recombinant polypeptide, defined as the concentration of the polypeptide in the culture medium, is a function of these two parameters (qP and IVC), calculated according to Porter et al. (Porter et al., 2010, Biotechnology Progress 26:1446-1455). Methods for measuring protein production are also described in more detail in the examples provided herein.
[0212] In one embodiment, the methods described herein generate cells with improved product quality. In one embodiment, the improved product quality results in an improvement, e.g., a 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more improvement in product quality compared to the amount, level, or content of the product produced by cells that have not been subjected to lower temperatures; or a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-fold or more improvement in product quality. Such an improvement in product quality can be exemplified, for example, by one or more of the following: i) increased or decreased disulfide bond scrambling (e.g., for antibody molecule products, increasing or decreasing disulfide bond scrambling as a result, e.g., of a desired isoform or conformation); ii) an increase in the amount or content of non-aggregated products (or a decrease in the amount or content of aggregated products); iii) an increase in the amount or abundance of properly folded or assembled product (or a decrease in the amount or abundance of misfolded, unfolded, partially assembled or non-assembled product), or an increase in the ratio of properly folded or assembled product to unfolded, misfolded, partially assembled or non-assembled product; iv) an increase in the amount or abundance of full-length products (or a decrease in fragmentation of the products); v) an increase in the desired post-translational modification (or a decrease in unmodified or mismodified products); vi) increasing or decreasing the heterogeneity of glycans (e.g., for glycosylation products); vii) An increase in the amount or content of functional product (or a decrease in the amount or content of non-functional or dysfunctional product), or an increase in the ratio of functional to non-functional or dysfunctional products.
[0213] Methods for measuring the product quality, e.g., improved product quality, of cells or cell lines generated as described herein are known in the art. In one embodiment, methods for determining the fidelity of the primary sequence of an expressed recombinant polypeptide product are known in the art, e.g., mass spectrometry. The increase in the amount or concentration of a properly folded product, e.g., an expressed recombinant polypeptide, can be determined by evaluating circular dichroism or intrinsic fluorescence of the expressed recombinant polypeptide. The increase in the amount or concentration of a functional product can be tested using various functional assays depending on the nature of the recombinant product, e.g., the recombinant polypeptide. For example, antibodies can be tested by ELISA or other immunoaffinity assays. Other methods for determining the increase in product quality, e.g., determining aggregation, post-translational modifications, scrambling of disulfide bonds, can be assessed by size exclusion chromatography, high performance liquid chromatography, dynamic light scattering (DLS) techniques, and protein electrophoresis (PAGE) methods.
[0214] In some embodiments, additional steps may be performed to improve product expression, e.g., transcription, translation and / or secretion of the product, or product quality, e.g., proper folding and / or primary sequence fidelity. Such additional steps include introducing an agent that improves product expression or product quality. In one embodiment, the agent that improves product expression or product quality can be a nucleic acid encoding a small molecule, polypeptide, or polypeptide that improves protein folding, e.g., a chaperone protein. In one embodiment, the agent that assists in protein folding includes a nucleic acid encoding a chaperone protein, e.g., BiP, PD1, or ERO1 (Chakravarthi and Bulleid, 2004; Borth et al., 2005; Davis et al., 2000). Other additional steps to improve product yield and quality include overexpression of transcription factors such as XBP1 and ATF6 (Tigges and Fussenegger, 2006; Cain et al., 2013; Ku et al., 2008), and overexpression of lectin-binding chaperone proteins such as calnexin and calreticulin (Chung et al., 2004). Overexpression of agents that aid or improve protein folding, product quality, and product yield, as described herein, can be achieved by introduction of exogenous nucleic acids encoding the agents. In another embodiment, an agent that improves product expression or product quality is a small molecule, e.g., DMSO, that can be added to the cell culture to improve product expression or product quality. In one embodiment, maintaining cells at a lower temperature, e.g., 1° C., 2° C., 3° C., 4° C., 5° C., 6° C., 7° C., 8° C., 9° C., or 10° C. lower than the temperature at which the cells normally grow, can improve product quality by reducing or eliminating product dissociation.
[0215] Any of the methods described herein can further include an additional selection step to identify cells that have high productivity or produce high quality products. For example, FAC selection can be utilized to select specific cells with a desired property, e.g., higher protein expression, e.g., of a folding protein, e.g., a chaperone.
[0216] In one aspect, the disclosure provides a method comprising a step for recovering or removing the recombinant polypeptide product. In embodiments in which the recombinant polypeptide is secreted from the cell, the method can comprise a step for removing, collecting or separating the recombinant polypeptide from the cell, the cell population, or the culture medium in which the cell is cultured. In an embodiment in which the recombinant polypeptide is intracellular, purification of the recombinant polypeptide product comprises separation of the recombinant polypeptide produced by the cell from any one or more of host cell proteins, host cell nucleic acids, host cell lipids, and / or other debris from the host cell.
[0217] In embodiments, the processes described herein provide a substantially pure protein product. As used herein, "substantially pure" means substantially free of pyrogens, substantially free of nucleic acids, and / or substantially free of endogenous cellular protein enzymes and host cell derived components, such as polymerases, ribosomal proteins, and chaperone proteins. A substantially pure protein product contains, for example, less than 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of contaminating endogenous proteins, nucleic acids, or other macromolecules derived from the host cell.
[0218] Methods for recovery and purification of products, such as recombinant polypeptides, are well established in the art. To recover recombinant polypeptide products, physical or chemical or physicochemical methods are used. The physical or chemical or physicochemical methods can be filtration methods, centrifugation methods, ultracentrifugation methods, extraction methods, lyophilization methods, precipitation methods, chromatography methods, or a combination of two or more of these methods. In one embodiment, the chromatography method comprises one or more of size exclusion chromatography (or gel filtration), ion exchange chromatography, such as anion or cation exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, and / or multimodal chromatography.
[0219] In an embodiment, the reduction in temperature is combined with a reduction in temperature along with a reduction in pH, a thioredoxin inhibitor, such as a metal ion, In an embodiment, the combined process is carried out in a bioreactor as described above.
[0220] Numbered embodiments The invention may be defined in any of the following numbered paragraphs.
[0221] 1. A method for producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: maintaining a redox potential difference from unstabilized product to stabilized product in the range of -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or 50 mV to -150 mV, e.g., -50 mV to -300 mV, during separation of cells from the production culture and supernatant harvest, wherein separation of cells from the production culture and supernatant harvest is performed without sparging or with sufficiently little sparging such that sparging does not substantially change the redox potential in the production culture and supernatant. Including, Thereby producing a stabilized product, e.g., an isolated stabilized protein. method.
[0222] 2. A method for producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: providing, e.g., establishing, in a late logarithmic growth production culture, a redox potential difference from non-stabilized product to stabilized product in the range of -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., -50 mV to -300 mV; maintaining a redox potential difference from unstabilized product to stabilized product in the range of -10mV to -1000mV, -20mV to -800mV, -30mV to -700mV, -40mV to -600mV, -50mV to -500mV, -50mV to -400mV, -50mV to -300mV, -50mV to -200mV, or -50mV to -150mV, e.g., -50mV to -300mV, during separation of cells from the production culture and supernatant harvest, wherein separation of cells from the production culture and supernatant harvest is performed without sparging or with sparging sufficiently little such that sparging does not substantially change the redox potential in the production culture and supernatant; Including, Thereby producing a stabilized product, e.g., an isolated stabilized protein. method.
[0223] 3. The method of any one of paragraphs 1 or 2, further comprising establishing an air saturation of greater than 10, 20, 30, 40, 50 or 60% to less than or equal to 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500%, for example, a dissolved oxygen tension (DOT) in the range of greater than 40% to less than or equal to 500%, during separation of the cells from the production culture.
[0224] 4. A method for producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: providing, e.g., establishing, in a late logarithmic growth production culture, a redox potential difference from non-stabilized product to stabilized product in the range of -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., -50 mV to -300 mV, and a dissolved oxygen tension (DOT) from the beginning of the production phase to the end of the production phase in the range of greater than 40% to 70% air saturation; The production culture is cultured at the end of the production phase at a temperature at or below which the cell line is normally cultured, T 回収 and cooling to a temperature of increasing the DOT to greater than 10, 20, 30, 40, 50, or 60% to less than 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500% air saturation, for example, greater than 40% to less than 500% air saturation, by sparging air or O2 gas into the production culture prior to separation of the cells from the production culture and harvesting of the supernatant; maintaining a redox potential difference from unstabilized product to stabilized product in the range of -10mV to -1000mV, -20mV to -800mV, -30mV to -700mV, -40mV to -600mV, -50mV to -500mV, -50mV to -400mV, -50mV to -300mV, -50mV to -200mV, or -50mV to -150mV, e.g., -50mV to -300mV, during separation of cells from the production culture and supernatant harvest, wherein separation of cells from the production culture and supernatant harvest is performed without sparging or with sparging sufficiently little such that sparging does not substantially change the redox potential in the production culture and supernatant; Including, Thereby producing a stabilized product, e.g., an isolated stabilized protein. method.
[0225] 5. Providing, e.g., adding, a transition metal in or to the production culture, the transition metal ion being Zn 2+ , Mn 4+ , Cu 2+ , Fe 3+ , Co 2+ , Cr 3+ and / or Ni 2+ The method according to any one of claims 1 to 4, further comprising the step of:
[0226] 6. The method of any one of paragraphs 1 to 5, wherein DOT is further maintained by one or more measures selected from the group consisting of inhibiting sparge nitrogen gas flow if enabled, inhibiting on-demand alkali control if enabled, inhibiting on-demand CO2 gas flow control if enabled, inhibiting feed addition if enabled, enabling headspace pressure if not enabled, and enabling headspace air / O2 flow if not enabled.
[0227] 7. A method for producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: (i) providing, e.g., establishing, a production culture, e.g., a post-logarithmic culture, comprising recombinant host cells expressing a product, e.g., a protein, with a redox potential difference from unstabilized product to stabilized product in the range of from -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., from -50 mV to -300 mV; (ii) In the later stage of the growth culture, when the redox potential difference from the non-stabilized product to the stabilized product is maintained in the range of 10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, for example, -50 mV to -300 mV, (iii) maintaining a redox potential difference from unstabilized product to stabilized product in the range of -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., -50 mV to -300 mV, during separation of cells from the production culture and supernatant harvest, wherein separation of cells from the production culture and supernatant harvest is performed without sparging or with sparging sufficiently minimal such that sparging does not substantially change the redox potential in the production culture and supernatant; Including, a. cooling the production culture to a temperature of 30° C. to 33° C., which is a temperature below the temperature at which the cell line is normally cultured or will normally be cultured after logarithmic growth phase has occurred; b. oxygenating the production culture to a dissolved oxygen tension (DOT) of greater than 40% to less than or equal to 70% of air saturation from the beginning of the production phase to the end of the production phase; c. Providing, e.g., adding, a transition metal in or to the production culture, the transition metal being Zn 2+ , Mn 4+ , Cu 2+ , Fe 3+ , Co 2+ , Cr 3+ and / or Ni 2+ A step selected from the group consisting of: d. providing, e.g., adding, dehydroascorbic acid or ascorbic acid, or a dehydroascorbic acid or ascorbic acid modifying component to the production culture; e. providing, e.g., adding, glutathione, e.g., oxidized and / or reduced glutathione, or a glutathione modifying component, to the production culture; or f. The production culture is subjected to T for separation of cells from the production culture and harvest of the supernatant. 産生 Temperatures below 12°C to 18°C (T 回収 Cooling to temperature Including, thereby producing a stabilized product, e.g., an isolated stabilized protein, or a preparation of a stabilized product, e.g., a stabilized protein; method.
[0228] 8. The method according to item 7, comprising steps a, b and f.
[0229] 9. The method according to item 7, comprising steps a, c and f.
[0230] 10. The method according to item 7, including b and c.
[0231] 11. The method according to item 7, comprising steps a, b, c and f.
[0232] 12. The method of any one of paragraphs 1 to 11, wherein the production culture has an oxygenation level of at least 10%, at least 30%, or between 30% and 70% air saturation.
[0233] 13. The method of claim 12, wherein the oxygen loading level is greater than 40% to 70% air saturation.
[0234] 14. The transition metal is Zn. 2+ , Mn 2+ and / or Cu 2+ Item 14. The method according to any one of items 4 to 13, wherein
[0235] 15. Zinc 2+ Item 15. The method according to any one of items 4 to 14, wherein the compound is present at a concentration of from 10, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, or 250 to 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, 500, 550, 600, 650, 700, or 1000 μM, for example, from 200 to 400 μM.
[0236] 16. Mn 2+ 16. The method of any one of paragraphs 4 to 15, wherein is present at a concentration of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, or 50 to 60, 70, 80, 90, 100, 120, 140, 160, 180 or 200 μM, for example, 10 to 100 μM.
[0237] 17. Cu 2+ 17. The method of any one of paragraphs 4 to 16, wherein the compound is present at a concentration of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, or 50 to 60, 70, 80, 90, 100, 120, 140, 160, 180, or 200 μM, for example, 10 to 100 μM.
[0238] 18. Zinc 2+is present at concentrations ranging from 200 to 400 μM, and Mn 2+ exists at concentrations of 10-100 μM, and Cu 2+ Item 18. The method according to any one of items 4 to 17, wherein the compound is present at a concentration of 10 to 100 μM.
[0239] 19. The method of any one of paragraphs 1 to 18, wherein the stabilized protein comprises an Nth cysteine residue and an N+1th cysteine residue, where N=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more, for example, N=1 or N=3.
[0240] 20. The method of claim 19, wherein in its native form, the stabilized protein contains a disulfide bond between the Nth cysteine residue and the N+1th cysteine residue.
[0241] 21.i) N=1 and in its native form the polypeptide contains a disulfide bond between the first and second cysteine residues; ii) N=3 and in its native form the polypeptide contains a disulfide bond between the third and fourth cysteine residues; or iii) N=3 and in its native form the polypeptide contains a disulfide bond between the first and second cysteine residues and a disulfide bond between the third and fourth cysteine residues; 21. The method according to item 20.
[0242] 22. The method of any one of paragraphs 1 to 21, wherein at least 80, 85, 90, 95, 96, 97, 98 or 99% by weight of the stabilization product, e.g., the stabilized protein, is in a predetermined state, e.g., a native conformation, e.g., as determined by size separation, e.g., by gel electrophoresis, e.g., by non-reducing gel electrophoresis.
[0243] 23. The method of any one of paragraphs 1 to 22, wherein the product is an antibody and at least 80, 85, 90, 95, 96, 97, 98 or 99% by weight of the antibody is in a predetermined state, e.g., a native conformation, e.g., as determined by size separation, e.g., by gel electrophoresis, e.g., by non-reducing gel electrophoresis.
[0244] 24. The method of any one of paragraphs 1 to 23, wherein the product is an antibody and at least 80, 85, 90, 95, 96, 97, 98, or 99% by weight of the antibody is a tetramer comprising two chains each comprising a light chain variable region and two chains each comprising a heavy chain variable region.
[0245] 25.T 回収 25. The method according to any one of paragraphs 4 to 24, wherein the pH is sufficiently low to inhibit dissociation of disulfide bonds.
[0246] 26. Cells, T 回収 26. The method according to any one of paragraphs 4 to 25, comprising isolating the production culture.
[0247] 27. A cell line is cultured at a first temperature, T 培養 Cultured in T 回収 27. The method according to any one of paragraphs 4 to 26, wherein the extract is recovered by
[0248] 28.T 回収 But, T 培養 28. The method of claim 27, wherein the temperature is at least 19°C to 25°C or less.
[0249] 29.T 回収 Item 4. The method according to any one of items 4 to 28, wherein the temperature is 12°C to 18°C, for example, 15°C.
[0250] 30.T 培養 30°C to 38°C.
[0251] 31. For example, the protein as a component of the supernatant is T回収 31. The method according to any one of claims 4 to 30, wherein the method is applied to a filter.
[0252] 32. The method of any one of paragraphs 1 to 31, wherein the cells are cultured in a bioreactor.
[0253] 33. After the production phase, the contents of the bioreactor are 回収 33. The method of claim 32, wherein the mixture is cooled to 33° C.
[0254] 34. Cell cultures are 回収 33. The method of claim 32, wherein the material is cooled by contact with a member, e.g., a cooling jacket, comprising a fluid, e.g., water, at a temperature appropriate to cause the material to melt.
[0255] 35. The method of any one of paragraphs 32 to 34, wherein the bioreactor has a volume of 1 to 250 milliliters, 250 milliliters to 50 liters, 50 to 800 liters, or 800 to 200,000 liters.
[0256] 36. The method of any one of paragraphs 32 to 35, wherein the bioreactor is a single-use bioreactor, e.g., a bioreactor designed to allow incubation of a cell culture and then be disposable, e.g., as described herein.
[0257] 37. The method according to any one of paragraphs 32 to 36, wherein the bioreactor comprises a bioprocess vessel, a shell, at least one agitator, at least one sparger, at least one gas filter inlet for overlaying the sparger(s) and headspace, at least one inlet, at least one harvest port, at least one sample port, and at least one probe.
[0258] 38. The method of any one of paragraphs 32 to 37, wherein the bioreactor includes processes and probes for monitoring and maintaining one or more parameters, such as pH, dissolved oxygen tension (DOT) or temperature.
[0259] 39. The bioreactor is a free-standing, biocompatible tank having a volume of at least 4000 L and at least one top impeller and at least one bottom impeller, wherein the at least one top impeller is a hydrofoil impeller and the impeller spacing (D) between the top and bottom impellers is 0.01 mm. s ) must be at least 1.229 × the diameter of the bottom impeller (D 底部 ), and up to 2×D 底部 and the liquid height above the top impeller (D o ) is at least 0.3 × the diameter of the top impeller (D 頂部 ), and up to 2.5×D 頂部 and the bottom clearance between the bottom of the tank and the center line of the bottom impeller (D c ) but at least 0.35×D 底部 Item 38. The method according to any one of items 32 to 37, wherein 40. The method of any one of paragraphs 32 to 39, wherein the bioreactor is operably linked to a collection vessel.
[0260] 41. The method of claim 40, wherein the collection vessel comprises or is configured to provide a headspace above the reservoir culture, e.g., the headspace comprises a gas, e.g., air or oxygen, or a mixture of a gas, e.g., air or air and oxygen.
[0261] 42. The method of claim 41, wherein the collection vessel is configured to allow collection of the supernatant in the headspace through the J-tube port such that the supernatant migrates or cascades down the wall(s) of the collection vessel.
[0262] 43. The method of claim 42, wherein the supernatant is transferred onto a surface, e.g., a wall, of the collection vessel in the headspace and flows along the surface back to the reservoir culture.
[0263] 44. The method of claim 43, wherein the movement or cascading of the supernatant in the collection vessel results in an increased oxygenation level of the supernatant.
[0264] 45. The method of any one of paragraphs 40 to 44, wherein the DOT of the supernatant is maintained in the collection vessel by surface aeration in a range of greater than 10, 20, 30, 40, 50 or 60% to less than 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500% air saturation, for example greater than 40% to less than 500% air saturation.
[0265] 46. The method of any one of paragraphs 40 to 45, wherein the collection vessel comprises a cooling device and mechanism for further cooling the reservoir culture to a temperature of 5°C to 8°C.
[0266] 47. The method of any one of paragraphs 40 to 46, wherein the collection vessel includes a mixer device capable of axial mixing and an addition port for a pH titrant.
[0267] 48. The method of any one of paragraphs 40 to 47, wherein the collection vessel comprises at least one headspace gas inlet and at least one gas outlet.
[0268] 49. The method of any one of paragraphs 40 to 48, wherein the collection vessel further comprises at least one air flow controller and at least one O2 flow controller for providing a mixture of air and O2.
[0269] 50. The method of any one of paragraphs 40 to 49, wherein the collection vessel contains sensors for detecting DOT, redox, temperature and pH of the supernatant.
[0270] 51. The method of claim 50, wherein the outputs of DOT, redox, temperature and pH sensors are used to effect changes in sparge rate, headspace, and addition of feed or supplements into the production culture of the bioreactor prior to separation; and addition of pH titrants into the harvest vessel.
[0271] 52. The method of claim 50, wherein the outputs of DOT, redox, temperature and pH sensors are used to effect changes in the addition of pH titrants into the collection vessel.
[0272] 53. The method of any one of paragraphs 40 to 52, wherein the bioreactor is connected to the collection vessel using a blockage-resistant tube.
[0273] 54. The method of claim 53, wherein the occlusion-resistant tube is a braided tube.
[0274] 55. The method of any one of paragraphs 40 to 54, wherein the flow path between the bioreactor and the harvest vessel includes a DOT and redox sensor / probe device.
[0275] 56. The method of claim 55, wherein the output of the DOT and redox sensors / probes is used to effect changes in sparge rate, headspace, and addition of feed or supplements into the production culture of the bioreactor prior to harvest.
[0276] 57. The method of any one of paragraphs 40 to 56, wherein the bioreactor includes an element, e.g., a line or nozzle, configured to deliver the culture to a surface defining the headspace of the bioreactor.
[0277] 58. The method of any one of paragraphs 40 to 57, wherein the bioreactor includes a second element, e.g., a line or nozzle, configured to deliver the culture to a surface defining the headspace of the bioreactor.
[0278] 59. The method of any one of paragraphs 1 to 58, further comprising monitoring the redox potential of cells in culture and simultaneously isolating proteins for the purpose of maintaining the redox potential.
[0279] 60. The method of claim 59, wherein monitoring the redox potential includes using an in-line monitoring probe, such as a Mettler Toledo as described herein.
[0280] 61. The method of claim 58, wherein the step of monitoring the redox potential comprises evaluating the redox state of a cellular factor that affects product stability, and the cellular factor may impair an enzyme or metabolic cofactor of the glutathione / reduced glutathione pathway, the thioredoxin / reduced thioredoxin pathway, or the pentose phosphate pathway (e.g., glutathione reductase, thioredoxin, glucose-6-phosphate, NADPH, NADP+, 6-phosphonoglucolactone, 6-phosphogluconic acid, or ribulose-5-phosphate).
[0281] 62. The method of any one of paragraphs 1 to 61, wherein the recombinant host cell is a CHO-K1 cell, a CHO-K1 SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knockout cell, a CHO FUT8 GS knockout cell, a CHOZN or a CHO derived cell, and the CHO GS knockout cell (e.g., a GSKO cell) is, for example, a CHO-K1SV GS knockout cell (Lonza Biologics, Inc.), and the CHO FUT8 knockout cell is, for example, a Potelligent® CHOK1 SV (Lonza Biologics, Inc.).
[0282] 63. The method of any one of paragraphs 1 to 61, wherein the recombinant host cell is a CHO-GSKO cell, the CHOXceed cell CHO GS knockout cell (e.g., a GS-CHO cell) is, for example, a CHO-K1SV knockout cell (Lonza Biologics, Inc.), and the CHO FUT8 knockout cell is, for example, a Potelligent® CHOK1 SV (Lonza Biologics, Inc.).
[0283] 64. The method of any one of clauses 1 to 61, wherein the recombinant host cell is HeLa, HEK293, HT1080, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK (baby hamster kidney cells), VERO, SP2 / 0, NS0, YB2 / 0, Y0, EB66, C127, L cells, COS, e.g., COS1 and COS7, QC1-3, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11 and CHOZN, or any cell derived therefrom.
[0284] 65. A stabilized protein produced by the method of any one of paragraphs 1 to 64.
[0285] 66. A pharmaceutical composition comprising the stabilized protein according to item 65.
[0286] 67. The pharmaceutical composition according to item 66, further comprising a pharma- ceutically acceptable carrier, diluent or excipient.
[0287] 68. A bioreactor capable of producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, wherein the bioreactor is capable of reducing the redox potential difference from the non-stabilized product to the stabilized product during separation of the cells from the production culture and harvesting of the supernatant from -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -60 mV to -700 mV, -80 mV to -900 mV, -90 mV to -100 mV, -100 mV to -150 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -5 ...20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -20 mV to -800 mV, -20 mV to -800 mV, -3 V, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., -50 mV to -300 mV, and separation of cells from the production culture and harvest of the supernatant is performed without sparging or with sufficiently little sparging such that sparging does not substantially change the redox potential in the production culture and supernatant. Bioreactor.
[0288] 69. A bioreactor capable of producing a stabilized product, e.g., a stabilized protein, expressed in a recombinant host cell, comprising: It is possible to provide, e.g., establish, in a late logarithmic growth production culture, a redox potential difference from non-stabilized product to stabilized product in the range of -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., -50 mV to -300 mV; and During the separation of cells from the production culture and the harvest of supernatant, the redox potential difference from the non-stabilized product to the stabilized product can be maintained in the range of -10mV to -1000mV, -20mV to -800mV, -30mV to -700mV, -40mV to -600mV, -50mV to -500mV, -50mV to -400mV, -50mV to -300mV, -50mV to -200mV, or -50mV to -150mV, e.g., -50mV to -300mV, and the separation of cells from the production culture and the harvest of supernatant is performed without sparging or with sparging sufficiently little such that the sparging does not substantially change the redox potential in the production culture and the supernatant. Bioreactor.
[0289] 70. The bioreactor of any one of paragraphs 68 or 69, wherein the bioreactor is capable of establishing a dissolved oxygen tension (DOT) in the range of greater than 10, 20, 30, 40, 50 or 60% to less than or equal to 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500% air saturation, for example greater than 40% to less than or equal to 500% air saturation, during separation of cells from the production culture.
[0290] 71. A bioreactor capable of producing a stabilized product, such as a stabilized protein, expressed in a recombinant host cell, comprising: in a late logarithmic growth production culture, it is possible to provide, e.g., establish, a redox potential difference from non-stabilized product to stabilized product in the range of -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., -50 mV to -300 mV, and a dissolved oxygen tension (DOT) from the beginning of the production phase to the end of the production phase in the range of greater than 40% to 70% air saturation; The production culture is cultured at the end of the production phase at a temperature at or below which the cell line is normally cultured, T 回収 It is possible to cool to a temperature; The DOT can be increased to a range of greater than 10, 20, 30, 40, 50, or 60% to 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500% air saturation, for example, greater than 40% to 500% air saturation, by sparging air or O2 gas into the production culture prior to removal of the production culture from the bioreactor; and During the separation of cells from the production culture and the harvest of supernatant, the redox potential difference from the non-stabilized product to the stabilized product can be maintained in the range of -10mV to -1000mV, -20mV to -800mV, -30mV to -700mV, -40mV to -600mV, -50mV to -500mV, -50mV to -400mV, -50mV to -300mV, -50mV to -200mV, or -50mV to -150mV, e.g., -50mV to -300mV, and the separation of cells from the production culture and the harvest of supernatant is performed without sparging or with sparging sufficiently little such that the sparging does not substantially change the redox potential in the production culture and the supernatant. Bioreactor.
[0291] 72. The bioreactor may further provide, for example add, a transition metal to or in the production culture, the transition metal being Zn 2+ , Mn 4+ , Cu 2+ , Fe 3+ , Co 2+ , Cr 3+ and / or Ni 2+ 72. The bioreactor of any one of paragraphs 68 to 71, selected from:
[0292] 73. The bioreactor of any one of paragraphs 68 to 72, wherein the bioreactor is further capable of maintaining DOT by one or more measures selected from the group consisting of inhibiting sparge nitrogen gas flow if enabled, inhibiting on-demand alkali control if enabled, inhibiting on-demand CO2 gas flow control if enabled, inhibiting feed addition if enabled, enabling headspace pressure if not enabled, and enabling headspace air / O2 flow if not enabled.
[0293] 74. A bioreactor capable of producing a stabilized product, such as a stabilized protein, expressed in a recombinant host cell, comprising: (i) providing, e.g., being capable of establishing, a production culture, e.g., a post-logarithmic growing culture, comprising a recombinant host cell expressing a product, e.g., a protein, with a redox potential difference from unstabilized product to stabilized product in the range of from -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., from -50 mV to -300 mV; (ii) during the later stage of the growth culture, the redox potential difference from the non-stabilized product to the stabilized product can be maintained in the range of -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., -50 mV to -300 mV; and (iii) during separation of cells from the production culture and supernatant harvest, the redox potential difference from unstabilized product to stabilized product can be maintained in the range of -10 mV to -1000 mV, -20 mV to -800 mV, -30 mV to -700 mV, -40 mV to -600 mV, -50 mV to -500 mV, -50 mV to -400 mV, -50 mV to -300 mV, -50 mV to -200 mV, or -50 mV to -150 mV, e.g., -50 mV to -300 mV, and separation of cells from the production culture and supernatant harvest is performed without sparging or with sparging sufficiently little such that sparging does not substantially change the redox potential in the production culture and supernatant. The bioreactor further comprises: a. It is possible to cool the production culture to a temperature of 30° C. to 33° C. after logarithmic growth phase has occurred, which is below the temperature at which the cell line is normally cultured; b. It is possible to oxygenate the production culture to a dissolved oxygen tension (DOT) of greater than 40% up to 70% of air saturation from the beginning of the production phase to the end of the production phase; c. A transition metal can be provided, e.g., added, in or to the production culture, the transition metal being Zn 2+ , Mn 4+ , Cu 2+ , Fe 3+ , Co 2+ , Cr 3+ and / or Ni 2+ Selected from; d. dehydroascorbic acid or ascorbic acid, or dehydroascorbic acid or ascorbic acid modifying components, can be provided, e.g., added, to the production culture; e. glutathione, e.g., oxidized and / or reduced glutathione, or glutathione modifying components, can be provided, e.g., added, to the production culture; or f. The production culture is subjected to T for separation of cells from the production culture and harvest of the supernatant. 産生Temperatures below 12°C to 18°C (T 回収 It is possible to cool to a temperature Bioreactor.
[0294] 75. The bioreactor according to paragraph 74, wherein the bioreactor is capable of a, b and f.
[0295] 76. The bioreactor according to paragraph 74, wherein the bioreactor is capable of a, c and f.
[0296] 77. The bioreactor according to paragraph 74, wherein the bioreactor is capable of b and c.
[0297] 78. A bioreactor according to item 74, wherein a, b, c and f are possible.
[0298] 79. The bioreactor of any one of paragraphs 68 to 77, operably linked to a collection vessel.
[0299] 80. The bioreactor of paragraph 79, wherein the collection vessel comprises or is configured to provide a headspace above the reservoir culture, e.g., the headspace comprises a gas, e.g., air or oxygen, or a mixture of a gas, e.g., air or air and oxygen.
[0300] 81. A bioreactor according to paragraph 80, configured to allow circulation of the culture in the headspace such that the culture moves or cascades down the wall(s) of the collection vessel.
[0301] 82. A bioreactor according to paragraph 81, wherein the culture from the reservoir culture is transferred onto a surface, e.g., onto a wall, of the bioreactor in the headspace and flows along the surface back to the reservoir culture.
[0302] 83. The bioreactor of paragraph 82, wherein the migration or cascading flow results in an increased oxygen loading level in the culture.
[0303] 84. The bioreactor of any one of paragraphs 79 to 83, wherein the harvest vessel is capable of maintaining the DOT of the reservoir culture in a range of greater than 10, 20, 30, 40, 50 or 60% to less than 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500% air saturation by surface aeration, for example greater than 40% to less than 500% air saturation.
[0304] 85. The bioreactor of any one of paragraphs 79 to 84, wherein the collection vessel comprises one or more components selected from the group consisting of a cooling device and cooling mechanism for further cooling the reservoir culture to a temperature of 5°C to 8°C; a mixer device capable of axial mixing and an addition port for a pH titrant; at least one headspace gas inlet and at least one gas outlet; at least one air flow controller and at least one O2 flow controller for providing a mixture of air and O2; and sensors for detecting DOT, redox, temperature and pH of the supernatant.
[0305] 86. A bioreactor as described in paragraph 85, wherein the output of the DOT, redox, temperature and pH sensors can result in changes in sparge rate, headspace, and addition of feed materials or nutritional supplements into the production culture of the bioreactor prior to separation; and changes in the addition of pH titrants into the harvest vessel.
[0306] 87. A bioreactor as described in paragraph 85, wherein the output of the DOT, redox, temperature and pH sensors can result in changes in the addition of pH titrants into the collection vessel.
[0307] 88. A bioreactor according to any one of paragraphs 79 to 87, which is connected to a collection vessel using a clog-resistant tube.
[0308] 89. The bioreactor of paragraph 88, wherein the blockage-resistant tube is a braided tube.
[0309] 90. The bioreactor of any one of paragraphs 79 to 88, wherein the flow path between the bioreactor and the harvest vessel includes DOT and redox sensor / probe devices.
[0310] 91. The bioreactor of any one of paragraphs 79 to 90, comprising an element, e.g., a line or nozzle, configured to deliver the culture to a surface defining the headspace of the collection vessel.
[0311] 92. The bioreactor of any one of paragraphs 79 to 91, comprising a second element, e.g., a line or nozzle, configured to deliver the culture to a surface defining the headspace of the collection vessel.
[0312] 93. The bioreactor of any one of paragraphs 68 to 92, which is a single-use bioreactor, e.g., a bioreactor as described herein, designed to allow incubation of a cell culture and then be disposable.
[0313] 94. The bioreactor according to any one of paragraphs 68 to 93, wherein the bioreactor comprises a bioprocess vessel, a shell, at least one agitator, at least one sparger, at least one gas filter inlet for the sparger(s) and headspace overlay, at least one inlet, at least one harvest port, at least one sample port, and at least one probe.
[0314] 95. The bioreactor is a free-standing biocompatible tank having a volume of at least 4000 L and at least one top impeller and at least one bottom impeller, wherein at least one top impeller is a hydrofoil impeller, and the impeller spacing (D) between the top and bottom impellers is 0.01 mm. s ) must be at least 1.229 × the diameter of the bottom impeller (D 底部 ), and up to 2×D 底部 and the liquid height above the top impeller (Do ) is at least 0.3 × the diameter of the top impeller (D 頂部 ), and up to 2.5×D 頂部 and the bottom clearance between the bottom of the tank and the center line of the bottom impeller (D c ) but at least 0.35×D 底部 93. The bioreactor of any one of paragraphs 68 to 92, wherein
[0315] 96. The method of any one of clauses 1 to 64, or the bioreactor of any one of clauses 68 to 95, wherein the product comprises a bispecific antibody.
[0316] 97. The method of any one of clauses 1 to 64 or the bioreactor of any one of clauses 68 to 95, wherein the product is a protein listed in Table 1, Table 2, Table 3 or Table 4.
[0317] 98. The method of any one of clauses 1 to 64, or the bioreactor of any one of clauses 68 to 95, wherein the product is an antibody, e.g., a monoclonal antibody, e.g., an IgG1 antibody.
[0318] 99. The method of any one of paragraphs 1 to 64, or the bioreactor of any one of paragraphs 68 to 95, wherein the recombinant host cell is derived from a mammalian cell, such as a mouse, rat, Chinese hamster ovary cell (CHO cell), Syrian hamster, monkey, ape, horse, ferret or cat cell.
[0319] 100. The method of any one of paragraphs 1 to 64, or the bioreactor of any one of paragraphs 68 to 95, wherein the recombinant host cell is derived from a non-mammalian cell, e.g., a duck, a parrot, a fish, an insect, a plant, a fungus, a yeast, a bacterium, e.g., E. coli, e.g., an archaea or an actinobacteria.
[0320] 101. The method of any one of paragraphs 1 to 64, or the bioreactor of any one of paragraphs 68 to 95, wherein the recombinant host cells are stem cells.
[0321] 102. The method of any one of paragraphs 1 to 64, or the bioreactor of any one of paragraphs 68 to 95, wherein the recombinant host cell is any differentiated form of a cell described herein.
[0322] 103. The method of any one of paragraphs 1 to 64, or the bioreactor of any one of paragraphs 68 to 95, wherein the recombinant host cell is a cell derived from any primary cell in culture.
[0323] 104. The method of any one of paragraphs 1 to 64, or the bioreactor of any one of paragraphs 68 to 95, wherein the recombinant host cell is a CHOK1SV, GS-KO or DUX-B11 cell. EXAMPLES
[0324] The present invention will be further described in detail by reference to the following examples. These examples are provided for illustrative purposes only and are not intended to be limiting unless otherwise specified. Therefore, the present invention should not be construed as being limited to the following examples in any way, but rather as embracing any and all variations that become evident as a result of the teachings provided herein.
[0325] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following examples specifically point out various aspects of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.
[0326] (Example 1) Cooling the cells reduces the oxygen depletion associated with retrieval and storage of cell samples Oxygen depletion is an identified and documented causal pathway for dissociation. The rate of depletion decreases with temperature. Figure 1 shows that the solubility of O2 increases inversely proportional to temperature (comparison of 37°C, 15°C and 5°C). The change in three other oxygen-related parameters at these three temperatures is also shown. Therefore, it was hypothesized that cooling the bioreactor / sample could similarly help prevent dissociation.
[0327] The mitigation strategy including cooling of the cells is shown in FIG. 2 for the bioreactor, primary storage chamber, and storage bags or bottles.
[0328] (Example 2) Harvest profiles of the two bioreactors with and without oxygenation of the harvest. The harvest profiles of the two bioreactors, with and without oxygen loading of the harvest, are shown in Figure 3. The data show a hypoxic event in the culture during harvest (close to 0%), consistent with the assumption of dissociation. In contrast, a profile is shown for a culture that remained oxygen loaded (approximately 20% at its lowest point) during harvest by implementing the mitigation strategy as shown.
[0329] (Example 3) Non-reduced SDS polyacrylamide gels with and without reduction Figure 4 is a representation of non-reducing SDS polyacrylamide gel samples prepared without (left panel) and with (right panel) reduction for an IgG1 monoclonal antibody. For the sample prepared without reduction, multiple bands are observed, indicative of dissociated polypeptide species. In contrast, a single high molecular weight band, giving no evidence of dissociation, is detected for the sample subjected to the reduction strategy shown in Figure 2. These results demonstrate that the reduction strategy, including cooling of the cells, suppresses protein dissociation.
[0330] No simple trends were observed between a single growth characteristic (maximum viable cell concentration, harvested viable cell concentration, IVC, viability at harvest) and dissociation. The absence of a trend does not exclude the possibility of an interaction between the growth parameter(s) and another parameter(s) that shows a trend together with dissociation.
[0331] (Example 4) Redox management Without wishing to be bound by theory, the following table illustrates how air flow, oxygen flow, oxygen content of the gas, and DOT are related in the methods and bioreactors of the present disclosure.
[0332] FIG. 5 shows the redox potential difference of the production culture of the baseline and optimized upstream processes using a combination of DOT at 60% air saturation, a higher process control of dissolved oxygen tension, and a change in process temperature after the cell growth phase (typically on day 6) from a control point of 36.5° C. to a control point of 33.0° C. In addition, the production culture was intermittently fed with a bolus feed with high levels of micronutrients such as copper, manganese and zinc salts from day 3 of culture to day 10 of culture. In another variation of the optimized upstream process, micronutrients were fed continuously from day 3 of culture until harvest on day 15 of culture. Increasing the application of pro-oxidative micronutrients from day 3 onwards gave a suitable redox potential difference of approximately −50 mV, which was further improved after a change in temperature to 33.0° C. and continued application of pro-oxidative micronutrients to approximately −115 mV. The product produced in the baseline process showed a more erratic behavior after the baseline cell clarification procedure. However, products were produced with redox potential optimized processes that produced products that were more resilient to baseline cell clarification procedures that may result in the cultures becoming exposed to a low or oxygen depleted environment during the harvest step. Unstable behavior for products made using these upstream processes was as follows: - Increased amount of product fragments after elution of the product from Protein A resin chromatography or after low pH treatment for virus inactivation. - Increased aggregation of the product after exposure to low pH holds typically used for virus inactivation during the manufacturing process. While the benefits of a more oxidative redox potential difference during product production would be beneficial, it is hypothesized that ensuring a similar oxidative redox potential difference during the harvesting step and storage of the supernatant could be beneficial as well. It is further anticipated that other pro-oxidant cell culture nutrients and cellular metabolites (e.g., iron III salts, cystine / cysteine, dehydroascorbic acid / ascorbic acid, and glutathione / glutathione-SH) may behave in a similar manner to those tested in the above examples.
[0333] (Example 5) temperature control 6 shows the temperature profile of the production culture when cooled prior to the harvest operation, and the sparge rates of the on-demand air and oxygen flows, which are matched to the cellular oxygen taken up by the production culture. In the event that the sparge rates fall below a process specific threshold, these sparge rates are fixed during the harvest operation. These fixed sparge rates can be: - A constant flow rate of oxygen from a minimum of 0 to a maximum flow rate, used immediately prior to the start of cooling of the culture. - A constant flow rate of air from a minimum flow rate to a maximum flow rate equal to the flow rate immediately prior to the start of cooling of the culture, to achieve an oxygen mass transfer coefficient kLa similar to that applied immediately prior to cooling for both air and oxygen on-demand flows.
[0334] (Example 6) Oxygen Management FIG. 7A shows an example of key process parameters in the production culture during harvest from a 1000 L single-use bioreactor using a disposable POD depth filter for cell culture clarification. In this example, the production culture was mixed and aerated with the same agitation (mixing) and aeration rates applied to the production culture to match the cellular oxygen demand. Cooling of the production culture stopped the cellular demand as previously described in FIG. 1. However, continued application of similar mixing and aeration rates ensures that the DOT of the culture continues to increase to a level limited by the percentage of oxygen enrichment of the sparge gas. Note that air saturates the dissolved oxygen in the culture up to 100% air saturation. Pure oxygen saturates the dissolved oxygen in the culture up to about 500% air saturation. Thus, for any given harvest, the production culture can be aerated with air or oxygen, or a combination of air and oxygen. Depending on the ratio of air and oxygen used, the dissolved oxygen in the culture can be variable and specific to the particular product or process, or production facility and equipment used to harvest the production culture (e.g., filter type, filter area, flow path between the bioreactor and the filter housing, and the flow path between the filter housing and the supernatant collection vessel, e.g., the harvest vessel), as well as the forward process operation pattern used within the facility (e.g., the period of time the supernatant is held before starting the purification process). Although the headspace pressure described in this example is not used, it is expected that the vessel can be operated at a headspace pressure higher than atmospheric pressure. This parameter can also be used to increase the dissolved oxygen in the culture beyond 100% air saturation. However, as the culture leaves the high pressure environment in the bioreactor, it is expected that it will be degassed and the DOT of the culture will decrease to equilibrate with the new pressure.
[0335] FIG. 7B shows an example of key process parameters in the production culture during harvest from a 50 L single-use bioreactor using a disposable POD depth filter for cell culture clarification. In this example, the production culture was mixed with the same agitation (mixing) applied to the production culture. However, the aeration rate was adjusted to a similar oxygen mass transfer coefficient kLa (h) required for the production culture just prior to being cooled in preparation for harvest. -1 The oxygen composition of the sparge gas is also increased to achieve a maximum culture DOT of approximately 200% air saturation (in this example, enriched to 40%).
[0336] An additional characteristic of the oxygen loading of the production culture during harvest can be defined by the period the culture is held at high DOT before harvest begins, which may be defined as within <1 hour of reaching the target temperature for harvest, or may be up to 24 hours of reaching the target temperature for harvest.
[0337] (Example 7) Bioreactor Characteristics During the harvest of a 1000L cGMP production culture, the flow rates of sparge air and oxygen depend on the scale of the operation, in this case a 1000L SUB. In a review of the performance of the harvest operation, the dissolved oxygen tension (DOT) of the production culture began to decrease during the later stages of harvest when approximately 400L of culture remained in the SUB. Extrapolation of the rate of DOT decrease suggests that the DOT of the culture drops to hypoxic levels (DOT at 0% air saturation) within 5 minutes. The hypoxic culture then enters the depth filter housing when further oxygen loading is not possible. Thus, the cell culture that entered the filter housing and the cells already retained from the earlier stages of filter clarification are expected to become oxygen starved. For this cell culture process and product, there is evidence that the occurrence of hypoxia during harvest can result in the product appearing "dissociated" when analyzed by a non-reducing SDS electrophoresis assay after an initial chromatography step using Protein A. See Figure 4.
[0338] The underlying mechanism is believed to be the release of cellular factors from cellular damage occurring in the clarification filter during the harvesting process that catalyze the reduction of disulfide bonds that hold and fold the product subunits (IgG heavy and light chains) together. These released cellular factors are typically active (and potentially damaging to the product) in their reduced state. However, in the bioreactor, while continuing to oxygenate the production culture with harvesting using a proper sparge rate, it is necessary to allow sufficient oxygen to be delivered to the depth filter and through the clarified supernatant. The dissolved oxygen delivered by the clarified supernatant prevents activation of the cellular factors to their reduced active state, thereby avoiding the catalytic progression of the dissociation reaction of protein disulfide bonds. However, currently there is no direct way to detect the DOT of the culture once the culture operating level falls below the DOT sensor in the bioreactor and while the culture is in the POD filter housing or when the clarified supernatant is collected in the bag. Due to this limitation, an alternative approach is applied where the cellular oxygen uptake rate of the culture increases beyond the capacity of the bioreactor, resulting in a downward trend in the DOT indicating oxygen is transferred into the cell culture, and this imbalance in oxygen transfer to and loss of dissolved oxygen from the culture (as indicated by a downward trend in the DOT) continues, followed by the application of continuous flow of sparged air and oxygen gas to ensure that the culture harvest proceeds smoothly without ever exhibiting product dissociation resulting in insufficient oxygen being available in the clarified supernatant to prevent activation of cellular factors.
[0339] Therefore, it is proposed to increase the flow rates of sparge air and oxygen fixed at low flow rates. Under the modified sparge conditions, the oxygen composition and volumetric flow rate of the sparge gas can saturate the culture to a higher DOT air saturation. In addition, the total volumetric sparge gas flow rate (total flow rate of air and oxygen) is increased to reach an increased oxygen mass transfer coefficient kLa equal to that required by the production culture to maintain the culture DOT at a process set point of at least 40% air saturation just before the production culture is further cooled in preparation for harvest.
[0340] Doctrine of Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the following claims.
[0341] The invention includes all variations, combinations and permutations of one or more limitations, elements, clauses and descriptive terms from one or more recited claims, where such limitations, elements, clauses and descriptive terms are introduced into another claim. When elements are presented as lists, for example in Markush group format, or as alternatives, each subgroup of the elements is also disclosed, and any element or elements can be deleted from the group.
[0342] In general, when the invention or aspects of the invention are referred to as comprising certain elements and / or features, it is to be understood that a particular embodiment of the invention or aspect of the invention consists of or consists essentially of such elements and / or features. It should also be noted that the terms "comprising" and "containing" are intended to be open and allow for the inclusion of additional elements or steps. When ranges are given, the endpoints are included. Furthermore, unless otherwise indicated or otherwise clear from the context and understanding of one of ordinary skill in the art, values expressed as ranges can assume any specific value or subrange within the ranges stated in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
Claims
1. 1. A method for producing a stabilized protein expressed in a recombinant host cell, comprising: During the post-exponential growth phase of the production culture, T 産生 providing a redox potential difference from the non-stabilized product to the stabilized product in the range of −50 mV to −150 mV at a temperature of 回収 and cooled to a temperature of T 回収 , T 産生 at least 5° C. below the maintaining a redox potential difference from non-stabilized product to stabilized product in the range of -50 mV to -150 mV while separating cells from the production culture and collecting the supernatant, wherein the separation of cells from the production culture and the collection of the supernatant are performed without sparging or with sparging sufficiently light that the sparging does not substantially change the redox potential difference in the production culture and the supernatant; and Thereby, a stabilized protein is produced.
2. 10. The method of claim 1, further comprising the step of establishing a dissolved oxygen tension (DOT) in the range of greater than 40% to less than 500% air saturation during separation of the cells from the production culture.
3. 1. A method for producing a stabilized protein expressed in a recombinant host cell, comprising: During the post-logarithmic growth phase of the production culture in the bioreactor, T 産生 providing a redox potential difference from the unstabilized protein to the stabilized protein in the range of -50 mV to -150 mV at a temperature of 0.5° C., wherein the dissolved oxygen tension (DOT) from the beginning of the production phase to the end of the production phase is in the range of greater than 40% to 70% air saturation; The production culture was cultured at the end of the production phase at T 回収 and cooling the mixture to a temperature of T 回収 , T 産生 at least 5° C. below the Before separation of cells from the production culture and harvesting of the supernatant, air or O 2 increasing the DOT to a range of greater than 40% to less than 500% air saturation by sparging gas; maintaining a redox potential difference from non-stabilized product to stabilized product in the range of -50 mV to -150 mV during separation of cells from the production culture and collection of the supernatant, wherein separation of cells from the production culture and collection of the supernatant is performed without sparging or with sparging sufficiently light that the sparging does not substantially change the redox potential difference in the production culture and the supernatant; Including, Thereby, a stabilized protein is produced.
4. Providing a transition metal in or to the production culture, the transition metal ion being Zn 2+ , Mn 4+ , Cu 2+ , Fe 3+ , Co 2+ , Cr 3+ And / or Ni 2+ The method according to claim 1 , further comprising the step selected from the group consisting of:
5. The DOT is suppressing sparge nitrogen gas flow, if effective; inhibiting on-demand alkalinity control, if effective; If valid, the on-demand CO 2 inhibiting gas flow control; inhibiting the addition of feed material, if effective; If not, enable the headspace pressure; and If not, headspace air / O 2 Enabling the flow, 5. The method according to claim 1 , further maintained by one or more measures selected from the group consisting of:
6. 1. A method for producing a stabilized protein expressed in a recombinant host cell, comprising: (i) providing a production culture in a bioreactor comprising recombinant host cells expressing the protein with a redox potential difference from unstabilized product to stabilized product in the range of −50 mV to −150 mV; (ii) maintaining the redox potential difference from the non-stabilized product to the stabilized product in the range of −50 mV to −150 mV during the culture phase after logarithmic growth; (iii) maintaining a redox potential difference from non-stabilized product to stabilized product in the range of −50 mV to −150 mV during separation of cells from the production culture and collection of the supernatant, wherein separation of cells from the production culture and collection of the supernatant are performed without sparging or with sparging sufficiently light that the sparging does not substantially change the redox potential difference in the production culture and the supernatant; Including, a. The production culture is incubated at a T of 30° C. to 33° C., which is a temperature at or below the temperature at which the cell line is normally cultured, after logarithmic growth phase has occurred. 産生 cooling to b. oxygenating the production culture to a dissolved oxygen tension (DOT) of greater than 40% to up to 70% of air saturation from the beginning of the production phase to the end of the production phase; c. Providing a transition metal in or to the production culture, the transition metal being Zn 2+ , Mn 4+ , Cu 2+ , Fe 3+ , Co 2+ , Cr 3+ And / or Ni 2+ The step is selected from the following: d. providing dehydroascorbic acid or ascorbic acid, or a dehydroascorbic acid or ascorbic acid modifying component to the production culture; e. providing glutathione to the production culture; or f. The production culture is incubated at a T of 12° C. to 18° C. for separation of cells from the production culture and collection of the supernatant. 回収 cooling to Including, Thereby, a stabilized protein is produced.
7. (1) a, b and f, (2) a, c and f, (3) b and c, or (4) a, b, c, and f The method of claim 6, comprising:
8. 10. The method of claim 1, 3 or 6, wherein the production culture has an oxygenation level of at least 10% of air saturation.
9. The transition metal is Zn 2+ , Mn 2+ And / or Cu 2+ The method according to claim 4, 6 or 7, wherein
10. Zinc 2+ is present at a concentration of 200 to 400 μM; 2+ is present at a concentration of 10-100 μM, or Cu 2+ The method of claim 9, wherein is present at a concentration of 10 to 100 μM.
11. 9. The method of claim 8, wherein the oxygenation level is greater than 40% to up to 70% air saturation.
12. i) N=1 and in its native form the polypeptide contains a disulfide bond between the first and second cysteine residues; ii) N=3 and in its native form the polypeptide contains a disulfide bond between the third and fourth cysteine residues; or iii) N=3 and in its native form, the polypeptide comprises a disulfide bond between the first and second cysteine residues and a disulfide bond between the third and fourth cysteine residues; The method according to claim 1, 3 or 6.
13. 10. The method of claim 1, 3 or 6, wherein at least 80% by weight of the stabilized protein is in a native conformation.
14. The method of claim 1, 3, or 6, wherein the protein is an antibody, and at least 80% by weight of the antibody is a tetramer comprising two chains each comprising a light chain variable region and two chains each comprising a heavy chain variable region.
15. The cells are heated to a first temperature, T 培養 and cultured in T 回収 It was collected by T 回収 The method of claim 12, wherein the pH is sufficiently low to inhibit dissociation of disulfide bonds.
16. The cells are T 回収 7. The method of claim 3 or 6, comprising the step of separating from the production culture by
17. The supernatant is 回収 7. The method according to claim 3 or 6, wherein the method is applied to a filter with
18. The bioreactor comprises: (1) has a volume of 800 to 200,000 liters; and / or (2) is a single-use bioreactor; and / or (3) A bioprocess vessel, including a shell, at least one agitator, at least one sparger, at least one gas filter inlet for the sparger(s) and headspace overlay, at least one inlet, at least one collection port, at least one sample port, and at least one probe; and / or (4) including processes and probes for monitoring and maintaining one or more parameters; and / or (5) A free-standing biocompatible tank having a volume of at least 4000 L and at least one top impeller and at least one bottom impeller, wherein the at least one top impeller is a hydrofoil impeller, the impeller spacing between the top impeller and the bottom impeller is at least 1.229 times the diameter of the bottom impeller and at most 2 times the diameter of the bottom impeller, the liquid height above the top impeller is at least 0.3 times the diameter of the top impeller and at most 2.5 times the diameter of the top impeller, and the bottom clearance between the bottom of the tank and the centerline of the bottom impeller is at least 0.35 times the diameter of the bottom impeller. The method according to claim 1, 3 or 6.
19. The production culture is subjected to T 回収 20. The method of claim 18, wherein the cooling is effected by contact with a member comprising a fluid at a temperature appropriate to cause the
20. the bioreactor is operably connected to a harvest vessel; (1) the collection vessel is configured to include or provide a headspace above the reservoir culture; and / or (2) the DOT in the supernatant is maintained in the collection vessel at a range of air saturation from greater than 40% to less than 500% by surface aeration; and / or (3) the collection vessel comprises a cooling device and mechanism for further cooling the reservoir culture to a temperature of 5° C. to 8° C.; and / or (4) the collection vessel includes a mixer device capable of axial mixing and an inlet for adding a pH titrant; and / or (5) the collection vessel includes at least one headspace gas inlet and at least one gas outlet; and / or (6) The collection vessel contains air and O 2 At least one air flow controller and at least one O 2 and / or a flow controller. (7) The method of claim 19, wherein the collection vessel comprises sensors for detecting dissolved oxygen tension (DOT), redox, temperature, and pH of the supernatant.
21. The flow path between the bioreactor and the harvest vessel includes a DOT and redox sensor / probe device, and the outputs of the DOT, redox, temperature and pH sensors are: (1) to effect changes in sparge rate, headspace, and feed or replenishment of additives into the production culture of the bioreactor prior to separation; and / or (2) to effect a change in the addition of a pH titrant into the collection vessel; and / or (3) to effect changes in sparge rate, headspace prior to harvest, and feeding or replenishing of additives into the production culture of the bioreactor; The method according to claim 20, wherein
22. (1) the bioreactor is connected to the collection vessel using clog-resistant tubing; and / or (2) The method of claim 20 or 21, wherein the flow path between the bioreactor and the collection vessel includes a DOT and redox sensor / probe device.
23. 22. The method of claim 20 or 21, wherein the bioreactor comprises a first, or first and second, line or nozzle configured to deliver a culture to a surface defining the headspace of the bioreactor.
24. 22. The method of claim 1, 3, 6, 20 or 21, further comprising monitoring the redox potential difference of cells in the culture and simultaneously isolating the protein for the purpose of maintaining the redox potential difference.
25. monitoring the redox potential difference includes using an in-line monitoring probe; 25. The method of claim 24, wherein monitoring the redox potential difference comprises assessing the redox state of a cellular factor that affects product stability, the cellular factor may comprise an enzyme or metabolic cofactor of the glutathione / reduced glutathione pathway, the thioredoxin / reduced thioredoxin pathway, or the pentose phosphate pathway.
26. 22. The method of claim 1, 3, 6, 20 or 21, wherein the recombinant host cell is a CHO-K1 cell, a CHO-K1 SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knockout cell, a CHO FUT8 GS knockout cell, a CHOZN, a CHO-derived cell, a HeLa cell, a HEK293 cell, a HT1080 cell, a H9 cell, a HepG2 cell, a MCF7 cell, a Jurkat cell, a NIH3T3 cell, a PC12 cell, a PER.C6 cell, a BHK (baby hamster kidney cell) cell, a VERO cell, a SP2 / 0 cell, a NS0 cell, a YB2 / 0 cell, a YO cell, an EB66 cell, a C127 cell, a L cell, a COS cell, a QC1-3 cell, or any cell derived therefrom.
27. T 回収 The expressed protein is isolated from the cultured cells, and a cell line expressing the protein is identified. 回収 10. The method of claim 1, 3 or 6, further comprising purifying the expressed protein when cooled to rt.
28. 28. The method of claim 27, wherein the protein is purified by a chromatographic method.
Citation Information
Patent Citations
Reaction solution for cell-free protein synthesis, method of preparing the same and protein synthesis method using the same
WO2003072796A1
